

DEX-0283



AC

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C12N 15/12, 15/11, 9/00, C12Q 1/68, A61K 48/00		A1	(11) International Publication Number: WO 00/58470 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/07906 (22) International Filing Date: 24 March 2000 (24.03.00)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/126,469 26 March 1999 (26.03.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71)(72) Applicants and Inventors: SRIKANTAN, Vasantha [IN/US]; 12813 Twinbrook Parkway, Rockville, MD 20851 (US). ZOU, Zhiqiang [CN/US]; 508 Palmspring Drive, Gaithersburg, MD 20878 (US). MOUL, Judd, W. [US/US]; 8917 Holly Leaf Lane, Bethesda, MD 20817 (US). SRIVASTAVA, Shiv [US/US]; 13216 Maplecrest Drive, Potomac, MD 20854 (US).			
(74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson, Farbow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).			
(54) Title: PROSTATE-SPECIFIC GENE, PCGEM1, AND METHODS OF USING PCGEM1 TO DETECT, TREAT, AND PREVENT PROSTATE CANCER			
<p>(57) Abstract</p> <p>A nucleic acid sequence that exhibits prostate-specific expression and overexpression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.</p>			
<p>STRATEGY FOR THE IDENTIFICATION OF GENE EXPRESSION ALTERATIONS IN PROSTATE CANCER</p> <pre>     graph TD       A["OCT EMBEDDED FROZEN PROSTATE TUMOR/NORMAL TISSUE"] --&gt; B["MAKE 6 μm SERIAL SECTIONS"]       B --&gt; C["HISTOLOGICAL EXAMINATION OF H &amp; E SLIDE"]       C --&gt; D["RNA PREPARATION"]       D --&gt; E["RT-PCR AMPLIFICATION USING ARBITRARY AND ANCHORED PRIMER CONTAINING 5' M13 OR T7 SEQUENCES"]       E --&gt; F["HIGH RESOLUTION GEL ELECTROPHORESIS (GENONYX SYSTEM) AND EXCISION OF DIFFERENTIALLY EXPRESSED BANDS"]       F --&gt; G["REAMPLIFICATION USING M13 AND T7 PRIMERS"]       G --&gt; H["PURIFICATION AND AUTOMATED DNA SEQUENCING ON ABI377 USING M13/T7 PRIMER"]       H --&gt; I["DNA SEQUENCE DATABASE SEARCH (NCBI, CGAP)"]       I --&gt; J["RT-PCR USING GENE SPECIFIC PRIMER FOR TUMOR SPECIFIC ALTERATIONS TO SCREEN RNA FROM DEFINED GROUP OF PATIENTS AND CELL LINES"]       J --&gt; K["ANALYZE EXPRESSION PATTERN FOR CLINICAL CORRELATIONS"]       J --&gt; L["STUDY BIOLOGICAL FUNCTION OF SELECTED GENES"]   </pre>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**PROSTATE-SPECIFIC GENE, PCGEM1, AND METHODS OF USING PCGEM1  
TO DETECT, TREAT, AND PREVENT PROSTATE CANCER**

**CROSS REFERENCE TO RELATED APPLICATIONS**

The present application claims the benefit of United States provisional application S.N. 60/126,469, filed March 26, 1999, the entire disclosure of which is relied upon and incorporated by reference.

**FIELD OF THE INVENTION**

The present invention relates to nucleic acids that are expressed in prostate tissue. More particularly, the present invention relates to the first of a family of novel, androgen-regulated, prostate-specific genes, PCGEM1, that is over-expressed in prostate cancer, and methods of using the PCGEM1 sequence and fragments thereof to measure the hormone responsiveness of prostate cancer cells and to detect, diagnose, prevent and treat prostate cancer and other prostate related diseases.

**BACKGROUND**

Prostate cancer is the most common solid tumor in American men (1). The wide spectrum of biologic behavior (2) exhibited by prostatic neoplasms poses a difficult problem in predicting the clinical course for the individual patient (3, 4). Public awareness of prostate specific antigen (PSA) screening efforts has led to an increased diagnosis of prostate cancer. The increased diagnosis and greater number of patients presenting with prostate cancer has resulted in wider use of radical prostatectomy for localized disease (5). Accompanying the rise in surgical intervention is the frustrating realization of the inability to predict organ-confined disease and clinical outcome for a given patient (5, 6). Traditional prognostic markers, such as grade, clinical stage, and pretreatment PSA have limited prognostic value for individual men. There is clearly a need to recognize and develop molecular and genetic biomarkers to improve prognostication and the management of patients with clinically localized prostate cancer. As with other common human neoplasia (7), the search for molecular and genetic biomarkers to better define the genesis and progression of prostate cancer is the key focus for cancer research investigations worldwide.

The new wave of research addressing molecular genetic alterations in prostate cancer is primarily due to increased awareness of this disease and the development of

newer molecular technologies. The search for the precursor of prostatic adenocarcinoma has focused largely on the spectrum of microscopic changes referred to as "prostatic intraepithelial neoplasia" (PIN). Bostwick defines this spectrum as a histopathologic continuum that culminates in high grade PIN and early invasive cancer (8). The morphologic and molecular changes include the progressive disruption of the basal cell-layer, changes in the expression of differentiation markers of the prostatic secretory epithelial cells, nuclear and nucleolar abnormalities, increased cell proliferation, DNA content alterations, and chromosomal and allelic losses (8, 9). These molecular and genetic biomarkers, particularly their progressive gain or loss, can be followed to trace the etiology of prostate carcinogenesis. Foremost among these biomarkers would be the molecular and genetic markers associated with histological phenotypes in transition between normal prostatic epithelium and cancer. Most studies so far seem to agree that PIN and prostatic adenocarcinoma cells have a lot in common with each other. The invasive carcinoma more often reflects a magnification of some of the events already manifest in PIN.

Early detection of prostate cancer is possible today because of the widely propagated and recommended blood PSA test that provides a warning signal for prostate cancer if high levels of serum PSA are detected. However, when used alone, PSA is not sufficiently sensitive or specific to be considered an ideal tool for the early detection or staging of prostate cancer (10). Combining PSA levels with clinical staging and Gleason scores is more predictive of the pathological stage of localized prostate cancer (11). In addition, new molecular techniques are being used for improved molecular staging of prostate cancer (12, 13). For instance, reverse transcriptase - polymerase chain reaction (RT-PCR) can measure PSA of circulating prostate cells in blood and bone marrow of prostate cancer patients.

Despite new molecular techniques, however, as many as 25 percent of men with prostate cancer will have normal PSA levels – usually defined as those equal to or below 4 nanograms per milliliter of blood (14). In addition, more than 50 percent of the men with higher PSA levels are actually cancer free (14). Thus, PSA is not an ideal screening tool for prostate cancer. More reliable tumor-specific biomarkers are

needed that can distinguish between normal and hyperplastic epithelium, and the preneoplastic and neoplastic stages of prostate cancer.

Identification and characterization of genetic alterations defining prostate cancer onset and progression is important in understanding the biology and clinical course of the disease. The currently available TNM staging system assigns the original primary tumor (T) to one of four stages (14). The first stage, T1, indicates that the tumor is microscopic and cannot be felt on rectal examination. T2 refers to tumors that are palpable but fully contained within the prostate gland. A T3 designation indicates the cancer has spread beyond the prostate into surrounding connective tissue or has invaded the neighboring seminal vesicles. T4 cancer has spread even further. The TNM staging system also assesses whether the cancer has metastasized to the pelvic lymph nodes (N) or beyond (M). Metastatic tumors result when cancer cells break away from the original tumor, circulate through the blood or lymph, and proliferate at distant sites in the body.

Recent studies of metastatic prostate cancer have shown a significant heterogeneity of allelic losses of different chromosome regions between multiple cancer foci (21-23). These studies have also documented that the metastatic lesion can arise from cancer foci other than dominant tumors (22). Therefore, it is critical to understand the molecular changes which define the prostate cancer metastasis especially when prostate cancer is increasingly detected in early stages (15-21).

Moreover, the multifocal nature of prostate cancer needs to be considered (22-23) when analyzing biomarkers that may have potential to predict tumor progression or metastasis. Approximately 50-60% of patients treated with radical prostatectomy for localized prostate carcinomas are found to have microscopic disease that is not organ confined, and a significant portion of these patients relapse (24). Utilizing biostatistical modeling of traditional and genetic biomarkers such as p53 and *bcl-2*, Bauer et al. (25-26) were able to identify patients at risk of cancer recurrence after surgery. Thus, there is clearly a need to develop biomarkers defining various stages of the prostate cancer progression.

Another significant aspect of prostate cancer is the key role that androgens play in the development of both the normal prostate and prostate cancer. Androgen

ablation, also referred to as "hormonal therapy," is a common treatment for prostate cancer, particularly in patients with metastatic disease (14). Hormonal therapy aims to inhibit the body from making androgens or to block the activity of androgen. One way to block androgen activity involves blocking the androgen receptor; however, that blockage is often only successful initially. For example, 70-80% of patients with advanced disease exhibit an initial subjective response to hormonal therapy, but most tumors progress to an androgen-independent state within two years (16). One mechanism proposed for the progression to an androgen-independent state involves constitutive activation of the androgen signaling pathway, which could arise from structural changes in the androgen receptor protein (16).

As indicated above, the genesis and progression of cancer cells involve multiple genetic alterations as well as a complex interaction of several gene products. Thus, various strategies are required to fully understand the molecular genetic alterations in a specific type of cancer. In the past, most molecular biology studies had focused on mutations of cellular proto-oncogenes and tumor suppressor genes (TSGs) associated with prostate cancer (7). Recently, however, there has been an increasing shift toward the analysis of "expression genetics" in human cancer (27-31), *i.e.*, the under-expression or over-expression of cancer-specific genes. This shift addresses limitations of the previous approaches including: 1) labor intensive technology involved in identifying mutated genes that are associated with human cancer; 2) the limitations of experimental models with a bias toward identification of only certain classes of genes, *e.g.*, identification of mutant *ras* genes by transfection of human tumor DNAs utilizing NIH3T3 cells; and 3) the recognition that the human cancer associated genes identified so far do not account for the diversity of cancer phenotypes.

A number of studies are now addressing the alterations of prostate cancer-associated gene expression in patient specimens (32-36). It is inevitable that more reports on these lines are to follow.

Thus, despite the growing body of knowledge regarding prostate cancer, there is still a need in the art to uncover the identity and function of the genes involved in prostate cancer pathogenesis. There is also a need for reagents and assays to

accurately detect cancerous cells, to define various stages of prostate cancer progression, to identify and characterize genetic alterations defining prostate cancer onset and progression, to detect micro-metastasis of prostate cancer, and to treat and prevent prostate cancer.

### SUMMARY OF THE INVENTION

The present invention relates to the identification and characterization of a novel gene, the first of a family of genes, designated PCGEM1, for Prostate Cancer Gene Expression Marker 1. PCGEM1 is specific to prostate tissue, is androgen-regulated, and appears to be over-expressed in prostate cancer. More recent studies associate PCGEM1 cDNA with promoting cell growth. The invention provides the isolated nucleotide sequence of PCGEM1 or fragments thereof and nucleic acid sequences that hybridize to PCGEM1. These sequences have utility, for example, as markers of prostate cancer and other prostate related diseases, and as targets for therapeutic intervention in prostate cancer and other prostate related diseases. The invention further provides a vector that directs the expression of PCGEM1, and a host cell transfected or transduced with this vector.

In another embodiment, the invention provides a method of detecting prostate cancer cells in a biological sample, for example, by using nucleic acid amplification techniques with primers and probes selected to bind specifically to the PCGEM1 sequence. The invention further comprises a method of selectively killing a prostate cancer cell, a method of identifying an androgen responsive cell line, and a method of measuring responsiveness of a cell line to hormone-ablation therapy.

In another aspect, the invention relates to an isolated polypeptide encoded by the PCGEM1 gene or a fragment thereof, and antibodies generated against the PCGEM1 polypeptide, peptides, or portions thereof, which can be used to detect, treat, and prevent prostate cancer.

Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the sequences, cells, vectors, and methods

particularly pointed out in the written description and claims herein as well as the appended drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the scheme for the identification of differentially expressed genes in prostate tumor and normal tissues.

Figure 2 depicts a differential display pattern of mRNA obtained from matched tumor and normal tissues of a prostate cancer patient. Arrows indicate differentially expressed cDNAs.

Figure 3 depicts the analysis of PCGEM1 expression in primary prostate cancers.

Figure 4 depicts the expression pattern of PCGEM1 in prostate cancer cell lines.

Figure 5a depicts the androgen regulation of PCGEM1 expression in LNCaP cells, as measured by reverse transcriptase PCR.

Figure 5b depicts the androgen regulation of PCGEM1 expression in LNCaP cells, as measured by Northern blot hybridization.

Figure 6a depicts the prostate tissue specific expression pattern of PCGEM1.

Figure 6b depicts a RNA master blot showing the prostate tissue specificity of PCGEM1.

Figure 7A depicts the chromosomal localization of PCGEM1 by fluorescent in situ hybridization analysis.

Figure 7B depicts a DAPI counter-stained chromosome 2 (left), an inverted DAPI stained chromosome 2 shown as G-bands (center), and an ideogram of chromosome 2 showing the localization of the signal to band 2q32(bar).

Figure 8 depicts a cDNA sequence of PCGEM1 (SEQ ID NO:1).

Figure 9 depicts an additional cDNA sequence of PCGEM1 (SEQ ID NO:2).

Figure 10 depicts the colony formation of NIH3T3 cell lines expressing various PCGEM1 constructs.

Figure 11 depicts the cDNA sequence of the promoter region of PCGEM1 SEQ ID NO:3.

Figure 12 depicts the cDNA of a probe, designated SEQ ID NO:4.

Figure 13 depicts the cDNAs of primers 1-3, designated SEQ ID NOs:5-7, respectively.

Figure 14 depicts the genomic DNA sequence of PCGEM1, designated SEQ ID NO:8.

Figure 15 depicts the structure of the PCGEM1 transcription unit.

Figure 16 depicts a graph of the hypothetical coding capacity of PCGEM1.

Figure 17 depicts a representative example of *in situ* hybridization results showing PCGEM1 expression in normal and tumor areas of prostate cancer tissues.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention relates to PCGEM1, the first of a family of genes, and its related nucleic acids, proteins, antigens, and antibodies for use in the detection, prevention, and treatment of prostate cancer (e.g., prostatic intraepithelial neoplasia (PIN), adenocarcinomas, nodular hyperplasia, and large duct carcinomas) and prostate related diseases (e.g., benign prostatic hyperplasia), and kits comprising these reagents.

Although we do not wish to be limited by any theory or hypothesis, preliminary data suggest that the PCGEM1 nucleotide sequence may be related to a family of non-coding poly A+RNA that may be implicated in processes relating to growth and embryonic development (40-44). Evidence presented herein supports this hypothesis. Alternatively, PCGEM1 cDNA may encode a small peptide.

#### **NUCLEIC ACID MOLECULES**

In a particular embodiment, the invention relates to certain isolated nucleotide sequences that are substantially free from contaminating endogenous material. A "nucleotide sequence" refers to a polynucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid construct. The nucleic acid molecule has been derived from DNA or RNA isolated at least once in substantially pure form and in a quantity or concentration enabling identification, manipulation, and recovery of its component nucleotide sequences by standard biochemical methods.

(such as those outlined in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)).

Nucleic acid molecules of the invention include DNA in both single-stranded and double-stranded form, as well as the RNA complement thereof. DNA includes, for example, cDNA, genomic DNA, chemically synthesized DNA, DNA amplified by PCR, and combinations thereof. Genomic DNA may be isolated by conventional techniques, e.g., using the cDNA of SEQ ID NO:1, SEQ ID NO:2, or suitable fragments thereof, as a probe.

The DNA molecules of the invention include full length genes as well as polynucleotides and fragments thereof. The full length gene may include the N-terminal signal peptide. Although a non-coding role of PCGEM1 appears likely, the possibility of a protein product cannot presently be ruled out. Therefore, other embodiments may include DNA encoding a soluble form, e.g., encoding the extracellular domain of the protein, either with or without the signal peptide.

The nucleic acids of the invention are preferentially derived from human sources, but the invention includes those derived from non-human species, as well.

#### Preferred Sequences

Particularly preferred nucleotide sequences of the invention are SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO: 8, as set forth in Figures 8, 9, and 14, respectively. Two cDNA clones having the nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:2, and the genomic DNA having the nucleotide sequence of SEQ ID NO: 8, were isolated as described in Example 2.

Thus, in a particular embodiment, this invention provides an isolated nucleic acid molecule selected from the group consisting of (a) the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO: 8; (b) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of (a) under conditions of moderate stringency in 50% formamide and about 6X SSC at about 42°C with washing conditions of approximately 60°C, about 0.5X SSC, and about 0.1% SDS; (c) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA

comprising the nucleic acid sequence of (a) under conditions of high stringency in 50% formamide and about 6X SSC, with washing conditions of approximately 68°C, about 0.2X SSC, and about 0.1% SDS; (d) an isolated nucleic acid molecule derived by *in vitro* mutagenesis from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8; (e) an isolated nucleic acid molecule degenerate from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8 as a result of the genetic code; and (f) an isolated nucleic acid molecule selected from the group consisting of human PCGEM1 DNA, an allelic variant of human PCGEM1 DNA, and a species homolog of PCGEM1 DNA.

As used herein, conditions of moderate stringency can be readily determined by those having ordinary skill in the art based on, for example, the length of the DNA. The basic conditions are set forth by Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2d ed. Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989), and include use of a prewashing solution for the nitrocellulose filters of about 5X SSC, about 0.5% SDS, and about 1.0 mM EDTA (pH 8.0), hybridization conditions of about 50% formamide, about 6X SSC at about 42°C (or other similar hybridization solution, such as Stark's solution, in about 50% formamide at about 42°C), and washing conditions of about 60°C, about 0.5X SSC, and about 0.1% SDS. Conditions of high stringency can also be readily determined by the skilled artisan based on, for example, the length of the DNA. Generally, such conditions are defined as hybridization conditions as above, and with washing at approximately 68°C, about 0.2X SSC, and about 0.1% SDS. The skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted as necessary according to factors such as the length of the probe.

#### Additional Sequences

Due to the known degeneracy of the genetic code, wherein more than one codon can encode the same amino acid, a DNA sequence can vary from that shown in SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8, and still encode PCGEM1. Such variant DNA sequences can result from silent mutations (e.g., occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.

The invention thus provides isolated DNA sequences of the invention selected from: (a) DNA comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8; (b) DNA capable of hybridization to a DNA of (a) under conditions of moderate stringency; (c) DNA capable of hybridization to a DNA of (a) under conditions of high stringency; and (d) DNA which is degenerate as a result of the genetic code to a DNA defined in (a), (b), or (c). Such sequences are preferably provided and/or constructed in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, that are typically present in eukaryotic genes. Sequences of non-translated DNA can be present 5' or 3' from an open reading frame, where the same do not interfere with manipulation or expression of the coding region. Of course, should PCGEM1 encode a polypeptide, polypeptides encoded by such DNA sequences are encompassed by the invention. Conditions of moderate and high stringency are described above.

In another embodiment, the nucleic acid molecules of the invention comprise nucleotide sequences that are at least 80% identical to a nucleotide sequence set forth herein. Also contemplated are embodiments in which a nucleic acid molecule comprises a sequence that is at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, or at least 99.9% identical to a nucleotide sequence set forth herein.

Percent identity may be determined by visual inspection and mathematical calculation. Alternatively, percent identity of two nucleic acid sequences may be determined by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et al. (*Nucl. Acids Res.* 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745, 1986, as described by Schwartz and Dayhoff, eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each

gap; and (3) no penalty for end gaps. Other programs used by one skilled in the art of sequence comparison may also be used.

The invention also provides isolated nucleic acids useful in the production of polypeptides. Such polypeptides may be prepared by any of a number of conventional techniques. A DNA sequence of this invention or desired fragment thereof may be subcloned into an expression vector for production of the polypeptide or fragment. The DNA sequence advantageously is fused to a sequence encoding a suitable leader or signal peptide. Alternatively, the desired fragment may be chemically synthesized using known techniques. DNA fragments also may be produced by restriction endonuclease digestion of a full length cloned DNA sequence, and isolated by electrophoresis on agarose gels. If necessary, oligonucleotides that reconstruct the 5' or 3' terminus to a desired point may be ligated to a DNA fragment generated by restriction enzyme digestion. Such oligonucleotides may additionally contain a restriction endonuclease cleavage site upstream of the desired coding sequence, and position an initiation codon (ATG) at the N-terminus of the coding sequence.

The well-known polymerase chain reaction (PCR) procedure also may be employed to isolate and amplify a DNA sequence encoding a desired protein fragment. Oligonucleotides that define the desired termini of the DNA fragment are employed as 5' and 3' primers. The oligonucleotides may additionally contain recognition sites for restriction endonucleases, to facilitate insertion of the amplified DNA fragment into an expression vector. PCR techniques are described in Saiki et al., *Science* 239:487 (1988); *Recombinant DNA Methodology*, Wu et al., eds., Academic Press, Inc., San Diego (1989), pp. 189-196; and *PCR Protocols: A Guide to Methods and Applications*, Innis et al., eds., Academic Press, Inc. (1990).

#### USE OF PCGEM1 NUCLEIC ACID OR OLIGONUCLEOTIDES

In a particular embodiment, the invention relates to PCGEM1 nucleotide sequences isolated from human prostate cells, including the complete genomic DNA (Figure 14, SEQ ID NO: 8), and two full length cDNAs: SEQ ID NO:1 (Figure 8) and SEQ ID NO:2 (Figure 9), and fragments thereof. The nucleic acids of the invention, including DNA, RNA, mRNA and oligonucleotides thereof, are useful in a variety of

applications in the detection, diagnosis, prognosis, and treatment of prostate cancer. Examples of applications within the scope of the present invention include, but are not limited to:

- amplifying PCGEM1 sequences;
- detecting a PCGEM1-derived marker of prostate cancer by hybridization with an oligonucleotide probe;
- identifying chromosome 2;
- mapping genes to chromosome 2;
- identifying genes associated with certain diseases, syndromes, or other conditions associated with human chromosome 2;
- constructing vectors having PCGEM1 sequences;
- expressing vector-associated PCGEM1 sequences as RNA and protein;
- detecting defective genes in an individual;
- developing gene therapy;
- developing immunologic reagents corresponding to PCGEM1-encoded products; and
- treating prostate cancer using antibodies, antisense nucleic acids, or other inhibitors specific for PCGEM1 sequences.

#### Detecting, Diagnosing, and Treating Prostate Cancer

The present invention provides a method of detecting prostate cancer in a patient, which comprises (a) detecting PCGEM1 mRNA in a biological sample from the patient; and (b) correlating the amount of PCGEM1 mRNA in the sample with the presence of prostate cancer in the patient. Detecting PCGEM1 mRNA in a biological sample may include: (a) isolating RNA from said biological sample; (b) amplifying a PCGEM1 cDNA molecule; (c) incubating the PCGEM1 cDNA with the isolated nucleic acid of the invention; and (d) detecting hybridization between the PCGEM1 cDNA and the isolated nucleic acid. The biological sample can be selected from the group consisting of blood, urine, and tissue, for example, from a biopsy. In a preferred embodiment, the biological sample is blood. This method is useful in both the initial diagnosis of prostate cancer, and the later prognosis of disease. This

method allows for testing prostate tissue in a biopsy, and after removal of a cancerous prostate, continued monitoring of the blood for micrometastases.

According to this method of diagnosing and prognosticating prostate cancer in a patient, the amount of PCGEM1 mRNA in a biological sample from a patient is correlated with the presence of prostate cancer in the patient. Those of ordinary skill in the art can readily assess the level of over-expression that is correlated with the presence of prostate cancer.

In another embodiment, this invention provides a vector, comprising a PCGEM1 promoter sequence operatively linked to a nucleotide sequence encoding a cytotoxic protein. The invention further provides a method of selectively killing a prostate cancer cell, which comprises introducing the vector to prostate cancer cells under conditions sufficient to permit selective killing of the prostate cells. As used herein, the phrase "selective killing" is meant to include the killing of at least a cell which is specifically targeted by a nucleotide sequence. The putative PCGEM1 promoter, contained in the 5' flanking region of the PCGEM1 genomic sequence, SEQ ID NO: 3, is set forth in Figure 11. Applicants envision that a nucleotide sequence encoding any cytotoxic protein can be incorporated into this vector for delivery to prostate tissue. For example, the cytotoxic protein can be ricin, abrin, diphtheria toxin, p53, thymidine kinase, tumor necrosis factor, cholera toxin, *Pseudomonas aeruginosa* exotoxin A, ribosomal inactivating proteins, or mycotoxins such as trichothecenes, and derivatives and fragments (e.g., single chains) thereof.

This invention also provides a method of identifying an androgen-responsive cell line, which comprises (a) obtaining a cell line suspected of being androgen-responsive, (b) incubating the cell line with an androgen; and (c) detecting PCGEM1 mRNA in the cell line, wherein an increase in PCGEM1 mRNA, as compared to an untreated cell line, correlates with the cell line being androgen-responsive.

The invention further provides a method of measuring the responsiveness of a prostatic tissue to hormone-ablation therapy, which comprises (a) treating the prostatic tissue with hormone-ablation therapy; and (b) measuring PCGEM1 mRNA in the prostatic tissue following hormone-ablation therapy, wherein a decrease in

PCGEM1 mRNA, as compared to an untreated cell line, correlates with the cell line responding to hormone-ablation therapy.

In another aspect of the invention, these nucleic acid molecules may be introduced into a recombinant vector, such as a plasmid, cosmid, or virus, which can be used to transfect or transduce a host cell. The nucleic acids of the present invention may be combined with other DNA sequences, such as promoters, polyadenylation signals, restriction enzyme sites, multiple cloning sites, and other coding sequences.

#### Probes

Among the uses of nucleic acids of the invention is the use of fragments as probes or primers. Such fragments generally comprise at least about 17 contiguous nucleotides of a DNA sequence. The fragment may have fewer than 17 nucleotides, such as, for example, 10 or 15 nucleotides. In other embodiments, a DNA fragment comprises at least 20, at least 30, or at least 60 contiguous nucleotides of a DNA sequence. Examples of probes or primers of the invention include those of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, as well as those disclosed in Table I.

Table I

Primer	Sequence (5'→3')	S/AS	Starting Base #	SEQ ID NO.
p413	TGGCAACAGGCAAGCAGAG	S	510	SEQ ID NO: 9
p414	GGCCAAAATAAAACCAACAT	AS	610	SEQ ID NO: 10
p489	GCAAATATGATTAAAGATACAAC	S	752	SEQ ID NO: 11
p490	GGTTGTATCTTAAATCATATTGC	AS	776	SEQ ID NO: 12
p491	ACTGTCTTTCATATATTCTCAATGC	S	559	SEQ ID NO: 13
p517	AAGTAGTAATTAAACATGGGAC	AS	1516	SEQ ID NO: 14
p518	TTTTCAATTAGGCAGCAACC	S	131	SEQ ID NO: 15
p519	GAATTGTCTTGTGATTGTTTTAG	S	1338	SEQ ID NO: 16
p560	CAATTCACAAAGACAATTCAAGTAAAG	AS	1355	SEQ ID NO: 17
p561	ACAATTAGACAATGTCCAGCTGA	AS	1154	SEQ ID NO: 18
p562	CTTGGCTGATATCATGAAGTGTC	AS	322	SEQ ID NO: 19
p623	AACCTTTGCCCTATGCCGTAAC	S	148	SEQ ID NO: 20
p624	GAGACTCCAACCTGATGATGT	AS	376	SEQ ID NO: 21
p839	GGTCACGTTGAGTCCCAGTG	AS	270	SEQ ID NO: 22

S/AS indicates whether the primer is Sense or AntiSense

Starting Base # indicates the starting base number with respect to the sequence of SEQ ID NO:1.

However, even larger probes may be used. For example, a particularly preferred probe is derived from PCGEM1 (SEQ ID NO: 1) and comprises nucleotides 116 to 1140 of that sequence. It has been designated SEQ ID NO: 4 and is set forth in Figure 12.

When a hybridization probe binds to a target sequence, it forms a duplex molecule that is both stable and selective. These nucleic acid molecules may be readily prepared, for example, by chemical synthesis or by recombinant techniques. A wide variety of methods are known in the art for detecting hybridization, including fluorescent, radioactive, or enzymatic means, or other ligands such as avidin/biotin.

In another aspect of the invention, these nucleic acid molecules may be introduced into a recombinant vector, such as a plasmid, cosmid, or virus, which can be used to transfect or transduce a host cell. The nucleic acids of the present invention may be combined with other DNA sequences, such as promoters, polyadenylation signals, restriction enzyme sites, multiple cloning sites, and other coding sequences.

Because homologs of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 8 from other mammalian species are contemplated herein, probes based on the human DNA sequence of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 8 may be used to screen cDNA libraries derived from other mammalian species, using conventional cross-species hybridization techniques.

In another aspect of the invention, one can use the knowledge of the genetic code in combination with the sequences set forth herein to prepare sets of degenerate oligonucleotides. Such oligonucleotides are useful as primers, *e.g.*, in polymerase chain reactions (PCR), whereby DNA fragments are isolated and amplified. Particularly preferred primers are set forth in Figures 13 and Table I and are designated SEQ ID NOS: 5-7 and 9-22, respectively. A particularly preferred primer pair is p518 (SEQ ID NO: 15) and p839 (SEQ ID NO: 22), which when used in PCR, preferentially amplifies mRNA, thereby avoiding less desirable cross-reactivity with genomic DNA.

#### Chromosome Mapping

As set forth in Example 3, the PCGEM1 gene has been mapped by fluorescent *in situ* hybridization to the 2q32 region of chromosome 2 using a bacterial artificial chromosome (BAC) clone containing PCGEU1 genomic sequence. Thus, all or a portion of the nucleic acid molecule of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:8, including oligonucleotides, can be used by those skilled in the art using well-known techniques to identify human chromosome 2, and the specific locus thereof, that contains the PCGEM1 DNA. Useful techniques include, but are not limited to, using the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or SE ID NO:8, or fragments thereof, including oligonucleotides, as a probe in various well-known techniques such as radiation hybrid mapping (high resolution), *in situ* hybridization to chromosome spreads (moderate resolution), and Southern blot hybridization to hybrid cell lines containing individual human chromosomes (low resolution).

For example, chromosomes can be mapped by radiation hybridization. First, PCR is performed using the Whitehead Institute/MIT Center for Genome Research Genebridge4 panel of 93 radiation hybrids

[\(\[http://www-genome.wi.mit.edu/ftp/distribution/human\\\_STS\\\_releases/july97/rhmap/genebridge4.html\]\(http://www-genome.wi.mit.edu/ftp/distribution/human\_STS\_releases/july97/rhmap/genebridge4.html\)\)](http://www-genome.wi.mit.edu/ftp/distribution/human_STS_releases/july97/rhmap/genebridge4.html). Primers are used which lie within a putative exon of the gene of interest and which amplify a product from human genomic DNA, but do not amplify hamster genomic DNA. The results of the PCRs are converted into a data vector that is submitted to the Whitehead/MIT Radiation Mapping site on the internet (<http://www-seq.wi.mit.edu>). The data is scored and the chromosomal assignment and placement relative to known Sequence Tag Site (STS) markers on the radiation hybrid map is provided. (The following web site provides additional information about radiation hybrid mapping: [http://www-genome.wi.mit.edu/ftp/distribution/human\\_STS\\_releases/july97/07-97.INTRO.html](http://www-genome.wi.mit.edu/ftp/distribution/human_STS_releases/july97/07-97.INTRO.html)).

#### Identifying Associated Diseases

As noted above, PCGEM1 has been mapped to the 2q32 region of chromosome 2. This region is associated with specific diseases, which include but are not limited to diabetes mellitus (insulin dependent), and T cell leukemia/lymphoma. Thus, the nucleic acids of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO:8, or fragments thereof, can be used by one skilled in the art using well-known techniques to analyze abnormalities associated with gene mapping to chromosome 2. This enables one to distinguish conditions in which this marker is rearranged or deleted. In addition, nucleotides of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8, or fragments thereof, can be used as a positional marker to map other genes of unknown location.

The DNA may be used in developing treatments for any disorder mediated (directly or indirectly) by defective, or insufficient amounts of PCGEM1, including prostate cancer. Disclosure herein of native nucleotide sequences permits the detection of defective genes, and the replacement thereof with normal genes. Defective genes may be detected in *in vitro* diagnostic assays, and by comparison of a native nucleotide sequence disclosed herein with that of a gene derived from a person suspected of harboring a defect in this gene.

Sense-Antisense

Other useful fragments of the nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of DNA (SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8). Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to about 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (*Cancer Res.* 48:2659, 1988) and van der Krol et al. (*BioTechniques* 6:958, 1988).

The biologic activity of PCGEM1 in assay cells and the over expression of PCGEM1 in prostate cancer tissues suggest that elevated levels of PCGEM1 promote prostate cancer cell growth. Thus, the antisense oligonucleotides to PCGEM1 may be used to reduce the expression of PCGEM1 and, consequently, inhibit the growth of the cancer cells.

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes. The antisense oligonucleotides thus may be used to block expression of proteins or to inhibit the function of RNA. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (*i.e.*, capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10448, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides. Such modifications may

modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, lipofection, CaPO<sub>4</sub>-mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus or adenovirus.

Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

#### POLYPEPTIDES AND FRAGMENTS THEREOF

The invention also encompasses polypeptides and fragments thereof in various forms, including those that are naturally occurring or produced through various techniques such as procedures involving recombinant DNA technology. Such forms include, but are not limited to, derivatives, variants, and oligomers, as well as fusion proteins or fragments thereof.

The polypeptides of the invention include full length proteins encoded by the nucleic acid sequences set forth above. The polypeptides of the invention may be membrane bound or they may be secreted and thus soluble. The invention also includes the expression, isolation and purification of the polypeptides and fragments of the invention, accomplished by any suitable technique.

The following examples further illustrate preferred aspects of the invention.

**EXAMPLE 1: Differential Gene Expression Analysis in Prostate Cancer**

Using the differential display technique, we identified a novel gene that is over-expressed in prostate cancer cells. Differential display provides a method to separate and clone individual messenger RNAs by means of the polymerase chain reaction, as described in Liang et al., *Science*, 257:967-71 (1992), which is hereby incorporated by reference. Briefly, the method entails using two groups of oligonucleotide primers. One group is designed to recognize the polyadenylate tail of messenger RNAs. The other group contains primers that are short and arbitrary in sequence and anneal to positions in the messenger RNA randomly distributed from the polyadenylate tail. Products amplified with these primers can be differentiated on a sequencing gel based on their size. If different cell populations are amplified with the same groups of primers, one can compare the amplification products to identify differentially expressed RNA sequences.

Differential display ("DD") kits from Genomyx (Foster City, California) were used to analyze differential gene expression. The steps of the differential display technique are summarized in Figure 1. Histologically well defined matched tumor and normal prostate tissue sections containing approximately similar proportions of epithelial cells were chosen from individual prostate cancer patients.

Genomic DNA-free total RNA was extracted from this enriched pool of cells using RNAzol B (Tel-Test, Inc., Friendswood, TX) according to manufacturer's protocol. The epithelial nature of the RNA source was further confirmed using cytokeratin 18 expression (45) in reverse transcriptase-polymerase chain reaction (RT-PCR) assays. Using arbitrary and anchored primers containing 5' M13 or T7 sequences (obtained from Biomedical Instrumentation Center, Uniformed Services University of the Health Sciences, Bethesda), the isolated DNA-free total RNA was amplified by RT-PCR which was performed using ten anchored antisense primers and four arbitrary sense primers according to the protocol provided by Hieroglyph™ RNA Profile Kit 1 (Genomyx Corporation, CA). The cDNA fragments produced by the RT-PCR assay were analyzed by high resolution gel electrophoresis, carried out by

using Genomyx™ LR DNA sequencer and LR-Optimized™ HR-1000™ gel formulations (Genomyx Corporation, CA).

A partial DD screening of normal/tumor tissues revealed 30 differentially expressed cDNA fragments, with 53% showing reduced or no expression in tumor RNA specimens and 47% showing over expression in tumor RNA specimen (Figure 2). These cDNAs were excised from the DD gels, reamplified using T7 and M13 primers and the RT PCR conditions recommended in Hieroglyph™ RNA Profile Kit-1 (Genomyx Corp., CA), and sequenced. The inclusion of T7 and M13 sequencing primers in the DD primers allowed rapid sequencing and orientation of cDNAs (Figure 1).

All the reamplified cDNA fragments were purified by Centricon-c-100 system (Amicon, USA). The purified fragments were sequenced by cycle sequencing and DNA sequence determination using an ABI 377 DNA sequencer. Isolated sequences were analyzed for sequence homology with known sequences by running searches through publicly available DNA sequence databases, including the National Center for Biotechnology Information and the Cancer Genome Anatomy Project. Approximately two-thirds of these cDNA sequences exhibited homology to previously described DNA sequences/genes e.g., ribosomal proteins, mitochondrial DNA sequences, growth factor receptors, and genes involved in maintaining the redox state in cells. About one-third of the cDNAs represented novel sequences, which did not exhibit similarity to the sequences available in publicly available databases. The PCGEM1 fragment, obtained from the initial differential display screening represents a 530 base pair (nucleotides 410 to 940 of SEQ ID NO: 1) cDNA sequence which, in initial searches, did not exhibit any significant homology with sequences in the publicly available databases. Later searching of the high throughput genome sequence (HTGS) database revealed perfect homology to a chromosome 2 derived uncharacterized, unfinished genomic sequence (accession # AC 013401).

#### EXAMPLE 2: Characterization of Full Length PCGEM1 cDNA Sequence

The full length of PCGEM1 was obtained by 5' and 3' RACE/PCR from the original 530 bp DD product (nucleotides 410 to 940 of PCGEM1 cDNA SEQ ID

NO:1) using a normal prostate cDNA library in lambda phage (Clontech, CA). The RACE/PCR products were directly sequenced. Lasergene and MacVector DNA analysis software were used to analyze DNA sequences and to define open reading frame regions. We also used the original DD product to screen a normal prostate cDNA library. Three overlapping cDNA clones were identified.

Sequencing of the cDNA clones was performed on an ABI-310 sequence analyzer and a new dRhodamine cycle sequencing kit (PE-Applied Biosystem, CA). The longest PCGEM1 cDNA clone, SEQ ID NO:1 (Figure 8), revealed 1643 nucleotides with a potential polyadenylation site, ATTAAA, close to the 3' end followed by a poly (A) tail. As noted above, although initial searching of PCGEM1 gene in publically available DNA databases (e.g., National Center for Biotechnology Information) using the BLAST program did not reveal any homology, a recent search of the HTGS database revealed perfect homology of PCGEM1 (using cDNA of SEQ ID NO: 1) to a chromosome 2 derived uncharacterized, unfinished genomic sequence (accession # AC 013401). One of the cDNA clones, SEQ ID NO:2 (Figure 9), contained a 123 bp insertion at 278, and this inserted sequence showed strong homology (87%) to Alu sequence. It is likely that this clone represented the premature transcripts. Sequencing of several clones from RT-PCR further confirmed the presence of the two forms of transcripts.

Sequence analysis did not reveal any significant long open reading frame in both strands. The longest ORF in the sense strand was 105 nucleotides (572-679) encoding 35 amino acid peptides. However, the ATG was not in a strong context of initiation. Although we could not rule out the coding capacity for a very small peptide, it is possible that PCGEM1 may function as a non-coding RNA.

The sequence of PCGEM1 cDNA has been verified by several approaches including characterization of several clones of PCGEM1 and analysis of PCGEM1 cDNAs amplified from normal prostate tissue and prostate cancer cell lines. We have also obtained the genomic clones of PCGEM1, which has helped to confirm the PCGEM1 cDNA sequence. The complete genomic DNA sequence of PCGEM1 (SEQ ID NO:8) is shown in Figure 14. In Figure 14 (and in the accompanying Sequence Listing), "Y" represents any one of the four nucleotide bases, cytosine,

thymine, adenine, or guanine. Comparison of the cDNA and genomic sequences revealed the organization of the PCGEM1 transcription unit from three exons (Figure 15: E, Exon; B: BamHI; H: HindIII; X: XbaI; R: EcoRI).

#### EXAMPLE 3: Mapping the Location of PCGEM1

Using fluorescent *in situ* hybridization and the PCGEM1 genomic DNA as a probe, we mapped the location of PCGEM1 on chromosome 2q to specific region 2q32 (Figure 7A). Specifically, a Bacterial Artificial Chromosome (BAC) clone containing the PCGEM1 genomic sequence was isolated by custom services of Genome Systems (St. Louis, Mo). PCGEM1-Bac clone 1 DNA was nick translated using spectrum orange (Vysis) as a direct label and fluorescent *in situ* hybridization was done using this probe on normal human male metaphase chromosome spreads. Counterstaining was done and chromosomal localization was determined based on the G-band analysis of inverted 4',6-diamidino-2-phenylindole (DAPI) images. (Figure 7B: a DAPI counter-stained chromosome 2 is shown on the left; an inverted DAPI stained chromosome 2 shown as G-bands is shown in the center; an ideogram of chromosome 2 showing the localization of the signal to band 2q32(bar) is shown on the right.) NU200 image acquisition and registration software was used to create the digital images. More than 20 metaphases were analyzed.

#### EXAMPLE 4: Analysis of PCGEM1 Gene Expression in Prostate Cancer

To further characterize the tumor specific expression of the PCGEM1 fragment, and also to rule out individual variations of gene expression alterations commonly observed in tumors, the expression of the PCGEM1 fragment was evaluated on a test panel of matched tumor and normal RNAs derived from the microdissected tissues of twenty prostate cancer patients.

Using the PCGEM1 cDNA sequence (SEQ ID NO:1), specific PCR primers (Sense primer 1 (SEQ ID NO: 5): 5' TGCCTCAGCCTCCCAAGTAAC 3' and Antisense primer 2 (SEQ ID NO: 6): 5' GGCCAAAATAAAACCAACAT 3') were designed for RT-PCR assays. Radical prostatectomy derived OCT compound (Miles Inc. Elkhart, IN) embedded fresh frozen normal and tumor tissues from prostate

cancer patients were characterized for histopathology by examining hematoxylin and eosin stained sections (46). Tumor and normal prostate tissues regions representing approximately equal number of epithelial cells were dissected out of frozen sections. DNA-free RNA was prepared from these tissues and used in RT-PCR analysis to detect PCGEM1 expression. One hundred nanograms of total RNA was reverse transcribed into cDNA using RT-PCR kit (Perkin-Elmer, Foster, CA). The PCR was performed using AmpliTaq Gold from Perkin-Elmer (Foster, CA). PCR cycles used were: 95°C for 10 minutes, 1 cycle; 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, 42 cycles, and 72°C for 5 minutes, 1 cycle followed by a 4°C storage. Epithelial cell-associated cytokeratin 18 was used as an internal control.

RT-PCR analysis of microdissected matched normal and tumor tissue derived RNAs from 23 CaP patients revealed tumor associated overexpression of PCGEM1 in 13 (56%) of the patients (Figure 5). Six of twenty-three (26%) patients did not exhibit detectable PCGEM1 expression in either normal or tumor tissue derived RNAs. Three of twenty-three (13%) tumor specimens showed reduced expression in tumors. One of the patients did not exhibit any change. Expression of housekeeping genes, cytokeratin-18 (Figure 3) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (data not shown) remained constant in tumor and normal specimens of all the patients (Figure 3). These results were further confirmed by another set of PCGEM1 specific primers (Sense Primer 3 (SEQ ID NO: 7): 5' TGGCACACAGGCAAGCAGAG 3' and Antisense Primer 2 (SEQ ID NO: 6): 5' GGCCAAAATAAAACCAAACAT 3'). Four of 16 (25%) patients did not exhibit detectable PCGEM1 expression in either normal or tumor tissue derived RNAs. Two of 16 (12.5%) tumor specimens showed reduced expression in tumors. These results of PCGEM1 expression in tumor tissues could be explained by the expected individual variations between tumors of different patients. Most importantly, initial DD observations were confirmed by showing that 45% of patients analyzed did exhibit over expression of PCGEM1 in tumor prostate tissues when compared to corresponding normal prostate tissue of the same individual.

**EXAMPLE 5: *In situ* Hybridization**

*In situ* hybridization was performed essentially as described by Wilkinson and Green (48). Briefly, OCT embedded tissue slides stored at -80°C were fixed in 4% PFA (paraformaldehyde), digested with proteinase K and then again fixed in 4% PFA. After washing in PBS, sections were treated with 0.25% acetic anhydride in 0.1M triethanolamine, washed again in PBS, and dehydrated in a graded ethanol series. Sections were hybridized with  $^{35}\text{S}$ -labeled riboprobes at 52°C overnight. After washing and RNase A treatment, sections were dehydrated, dipped into NTB-2 emulsion and exposed for 11 days at 4°C. After development, slides were lightly stained with hematoxylin and mounted for microscopy. In each section, PCGEM1 expression was scored as percentage of cells showing  $^{35}\text{S}$  signal: 1+, 1-25%; 2+, 25-50%; 3+, 50-75%, 4+, 75-100%.

Paired normal (benign) and tumor specimens from 13 patients were tested using *in situ* hybridization. A representative example is shown in Figure 17. In 11 cases (84%) tumor associated elevation of PCGEM1 expression was detected. In 5 of these 11 patients the expression of PCGEM1 increased to 1+ in the tumor area from an essentially undetectable level in the normal area (on the 0 to 4+ scale). Tumor specimens from 4 of 11 patients scored between 2+ (example shown in Figure 17B) and 4+. Two of 11 patients showed focal signals with 3+ score in the tumor area, and one of these patients had similar focal signal (2+) in an area pathologically designated as benign. In the remaining 2 of the 13 cases there was no detectable signal in any of the tissue areas tested. The results indicate that PCGEM1 expression appears to be restricted to glandular epithelial cells. (Figure 17 shows an example of *in situ* hybridization of  $^{35}\text{S}$  labeled PCGEM1 riboprobe to matched normal (A) versus tumor (B) sections of prostate cancer patients. The light gray areas are hematoxylin stained cell bodies, the black dots represent the PCGEM1 expression signal. The signal is background level in the normal (A), 2+ level in the tumor (B) section. The magnification is 40x.)

**EXAMPLE 6: PCGEM1 Gene Expression in Prostate Tumor Cell Lines**

PCGEM1 gene expression was also evaluated in established prostate cancer cell lines: LNCaP, DU145, PC3 (all from ATCC), DuPro (available from Dr. David Paulson, Duke University, Durham, NC), and an E6/E7 - immortalized primary prostate cancer cell line, CPDR1 (47). CPDR1 is a primary CaP derived cell line immortalized by retroviral vector, LXSN 16 E6 E7, expressing E6 and E7 gene of the human papilloma virus 16. LNCaP is a well studied, androgen-responsive prostate cancer cell line, whereas DU145, PC3, DuPro and CPDR1 are androgen-independent and lack detectable expression of the androgen receptor. Utilizing the RT-PCR assay described above, PCGEM1 expression was easily detectable in LNCaP (Figure 4). However, PCGEM1 expression was not detected in prostate cancer cell lines DU145, PC3, DuPro and CPDR. Thus, PCGEM1 was expressed in the androgen-responsive cell line but not in the androgen-independent cell lines. These results indicate that hormones, particularly androgen, may play a key role in regulating PCGEM1 expression in prostate cancer cells. In addition, the results suggest that PCGEM1 expression may be used to distinguish between hormone responsive tumor cells and more aggressive hormone refractory tumor cells.

To test if PCGEM1 expression is regulated by androgens, we performed experiments evaluating PCGEM1 expression in LNCaP cells (ATCC) cultured with and without androgens. Total RNA from LNCaP cells, treated with synthetic androgen R1881 obtained from (DUPONT, Boston, MA), were analyzed for PCGEM1 expression. Both RT-PCR analysis (Figure 5a) and Northern blot analysis (Figure 5b) were conducted as follows.

LNCaP cells were maintained in RPMI 1640 (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, Life Technologies, Inc., Gaithersburg, MD) and experiments were performed on cells between passages 20 and 35. For the studies of NKX3.1 gene expression regulation, charcoal/dextran stripped androgen-free FBS (cFBS, Gemini Bio-Products, Inc., Calabasas, CA) was used. LNCaP cells were cultured first in RPMI 1640 with 10% cFBS for 4 days and then stimulated with a non-metabolizable androgen analog R1881 (DUPONT, Boston, MA) at different concentrations for different times as

shown in Figure 5A. LNCaP cells identically treated but without R1881 served as control. Poly A+ RNA derived from cells treated with/without R1881 was extracted at indicated time points with RNAzol B (Tel-Test, Inc, TX) and fractionated (2 $\mu$ g/lane) by running on 1% formaldehyde-agarose gel and transferred to nylon membrane. Northern blots were analyzed for the expression of PCGEM1 using the nucleic acid molecule set forth in SEQ ID NO: 4 as a probe. The RNA from LNCaP cells treated with R1881 and RNA from control LNCaP cells were also analyzed by RT-PCR assays as described in Example 4.

As set forth in Figures 5a and 5b, PCGEM1 expression increases in response to androgen treatment. This finding further supports the hypothesis that the PCGEM1 expression is regulated by androgens in prostate cancer cells.

#### EXAMPLE 7: Tissue Specificity of PCGEM1 Expression

Multiple tissue Northern blots (Clontech, CA) conducted according to the manufacturer's directions revealed prostate tissue-specific expression of PCGEM1. Polyadenylate RNAs of 23 different human tissues (heart, brain, placenta, lung, liver skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood, stomach, thyroid, spinal cord, lymph node, trachea, adrenal gland and bone marrow) were probed with the 530 base pair PCGEM1 cDNA fragment (nucleotides 410 to 940 of SEQ ID NO:1). A 1.7 kilobase mRNA transcript hybridized to the PCGEM1 probe in prostate tissue (Figure 6a). Hybridization was not observed in any of the other human tissues (Figure 6a). Two independent experiments revealed identical results.

Additional Northern blot analyses on an RNA master blot (Clontech, CA) conducted according to the manufacturer's directions confirm the prostate tissue specificity of the PCGEM1 gene (Figure 6b). Northern blot analyses reveal that the prostate tissue specificity of PCGEM1 is comparable to the well known prostate marker PSA (77mer oligo probe) and far better than two other prostate specific genes PSMA (234 bp fragment from PCR product) and NKX3.1 (210 bp cDNA). For instance, PSMA is expressed in the brain (37) and in the duodenal mucosa and a subset of proximal renal tubules (38). While NKX3.1 exhibits high levels of

expression in adult prostate, it is also expressed in lower levels in testis tissue and several other tissues (39).

#### **EXAMPLE 8: Biologic functions of the PCGEM1**

The tumor associated PCGEM1 overexpression suggested that the increased expression of PCGEM1 may favor tumor cell proliferation. NIH3T3 cells have been extensively used to define cell growth promoting functions associated with a wide variety of genes (40-44). Utilizing pcDNA3.1/Hygro(+/-)(Invitrogen, CA), PCGEM1 expression vectors were constructed in sense and anti-sense orientations and were transfected into NIH3T3 cells, and hygromycin resistant colonies were counted 2-3 weeks later. Cells transfected with PCGEM1 sense construct formed about 2 times more colonies than vector alone in three independent experiments (Figure 10). The size of the colonies in PCGEM1 sense construct transfected cells were significantly larger. No appreciable difference was observed in the number of colonies between anti-sense PCGEM1 constructs and vector controls. These promising results document a cell growth promoting/cell survival function(s) associated with PCGEM1.

The function of PCGEM1, however, does not appear to be due to protein expression. To assess this hypothesis, we used the TestCode program (GCG Wisconsin Package, Madison, WI), which identifies potential protein coding sequences of longer than 200 bases by measuring the non-randomness of the composition at every third base, independently from the reading frames. Analysis of the PCGEM1 cDNA sequence revealed that, at greater than 95% confidence level, the sequence does not contain any region with protein coding capacity (Figure 16A). Similar results were obtained when various published non-coding RNA sequences were analyzed with the TestCode program (data not shown), while known protein coding regions of similar size i.e., alpha actin (Figure 16B) can be detected with high fidelity. (In Figure 16, evaluation of the coding capacity of the PCGEM1 (A) and the human alpha actin (B), is performed independently from the reading frame, by using the TestCode program. The number of base pairs is indicated on the X- axis, the TestCode values are shown on the Y-axis. Regions of longer than 200 base pairs

above the upper line (at 9.5 value) are considered coding, under the lower line (at 7.3 value) are considered non-coding, at a confidence level greater than 95%).

The Codon Preference program (GCG Wisconsin Package, Madison, WI), which locates protein coding regions in a reading frame specific manner further suggested the absence of protein coding capacity in the PCGEM1 gene (see [www.cpd.org](http://www.cpd.org)). *In vitro* transcription/translation of PCGEM1 cDNA did not produce a detectable protein/peptide. Although we can not unequivocally rule out the possibility that PCGEM1 codes for a short unstable peptide, at this time both experimental and computational approaches strongly suggest that PCGEM1 cDNA does not have protein coding capacity. (It should be recognized that conclusions regarding the role of PCGEM1 are speculative in nature, and should not be considered limiting in any way.

The most intriguing aspect of PCGEM1 characterization has been its apparent lack of protein coding capacity. Although we have not completely ruled out the possibility that PCGEM1 codes for a short unstable peptide, careful sequencing of PCGEM1 cDNA and genomic clones, computational analysis of PCGEM1 sequence, and *in vitro* transcription/translation experiments (data not shown) strongly suggest a non-coding nature of PCGEM1. It is interesting to note that an emerging group of novel mRNA-like non-coding RNAs are being discovered whose function and mechanisms of action remain poorly understood (49). Such RNA molecules have also been termed as "RNA riboregulators" because of their function(s) in development, differentiation, DNA damage, heat shock responses and tumorigenesis (40-42, 50). In the context of tumorigenesis, the *H19*, *His-1* and *Bic* genes code for functional non-coding mRNAs (50). In addition, a recently reported prostate cancer associated gene, DD3 also appears to exhibit a tissue specific non-coding mRNA (51). In this regard it is important to point out that PCGEM1 and DD3 may represent a new class of prostate specific genes. The recent discovery of a steroid receptor co-activator as an mRNA, lacking protein coding capacity further emphasizes the role of RNA riboregulators in critical biochemical function(s) (52). Our preliminary results showed that PCGEM1 expression in NIH3T3 cells caused a significant increase in the size of colonies in a colony forming assay and suggests that PCGEM1 cDNA confers

cell proliferation and/or cell survival function(s). Elevated expression of PCGEM1 in prostate cancer cells may represent a gain in function favoring tumor cell proliferation/survival. On the basis of our first characterization of PCGEM1 gene, we propose that PCGEM1 belongs to a novel class of prostate tissue specific genes with potential functions in prostate cell biology and the tumorigenesis of the prostate gland.

In summary, utilizing surgical specimens and rapid differential display technology, we have identified candidate genes of interest with differential expression profile in prostate cancer specimens. In particular, we have identified a novel nucleotide sequence, PCGEM1, with no match in the publicly available DNA databases (except for the homology shown in the high throughput genome sequence database, discussed above). A PCGEM1 cDNA fragment detected a 1.7 kb mRNA on Northern blots with selective expression in prostate tissue. Furthermore, this gene was found to be up-regulated by the synthetic androgen, R1881. Careful analysis of microdissected matched tumor and normal tissues further revealed PCGEM1 over-expression in a significant percentage of prostate cancer specimens. Thus, we have provided a gene with broad implications for the diagnosis, prevention, and treatment of prostate cancer.

The specification is most thoroughly understood in light of the teachings of the references cited within the specification which are hereby incorporated by reference. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention.

## REFERENCES

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics. *CA Cancer J. Clin.*, 46:5-27, 1996.
2. Visakorpi T, Kallioniemi OP, Koivula T and Isola J: New prognostic factors in prostate carcinoma. *Eur. Uro.*, 24:438-449, 1993.
3. Mostofi FK: Grading of prostate carcinoma. *Cancer Chemothera Rep.*, 59:111, 1975.
4. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE: An assessment of radical prostatectomy. Time trends, Geographical Variations and Outcomes. *JAMA*, 269:2633-2636, 1993.
5. Partin AW and Oesterling JE: The clinical usefulness of prostate-specific antigen: update 1994. *J. Urol.*, 152:1358-1368, 1994.
6. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, and Wennberg JE: A structured literature review of treatment for localized CaP. *Arch. Fam. Med.*, 2:487-493, 1993.
7. Weinberg RA: How cancer arises. *Sci. Amer.*, 269:62-70, 1996.
8. Bostwick DG: High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. *Cancer*, 75:1823-1836, 1995.
9. Bostwick DG, Pacelli A, Lopez-Beltran A: Molecular Biology of Prostatic Intraepithelial Neoplasia. *The Prostate*, 29:117-134, 1996.
10. Pannek J, Partin AW: Prostate specific antigen: What's new in 1997. *Oncology*, 11:1273-1278, 1997.
11. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA*, 277:1445-1451, 1997.
12. Gomella LG, Raj GV, Moreno JG: Reverse transcriptase polymerase chain reaction for prostate specific antigen in management of prostate cancer. *J. Urol.*, 158:326-337, 1997.
13. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava, S, Moul JW: Detection of PSA-expressing prostatic cells in bone marrow of radical prostatectomy patients by sensitive reverse transcriptase-polymerase chain reaction (RT-PCR). 1998 International Symposium on Biology of Prostate growth, National Institutes of Health, p. 83, 1998.
14. Garnick MB, Fair WR: Prostate cancer. *Sci. Amer.*, 275:83, 1998.
15. Moul JW, Gaddipati J, and Srivastava S: 1994. Molecular biology of CaP. Oncogenes and tumor suppressor genes. *Current Clinical Oncology*: CaP. (Eds. Dawson, N.A. and Vogelzang, N.J.), Wiley-Liss Publications, 19-46.
16. Lalani E-N, Laniado ME and Abel PD: Molecular and cellular biology of prostate cancer. *Cancer and Mets. Rev.* 16:29-66, 1997.

17. Shi XB, Gumerlock PH, deVere White RW: Molecular Biology of CaP *World J. Urol.*; 14, 318-328, 1996.
18. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW and Srivastava S: The role of p53 tumor suppressor gene in CaP: a possible biomarker? *Urology*, 48:971-979, 1996.
19. Bova GS and Issacs WB: Review of allelic loss and gain in prostate cancer. *World J Urol.*, 14:338-346, 1996.
20. Issacs WB and Bova GS: Prostate Cancer: The Genetic Basis of Human Cancer. Eds. Vogelstein B, and Kinzler KW, McGraw-Hill Companies, Inc., pp. 653-660, 1998.
21. Srivastava S and Moul JW: Molecular Progression of Prostate Cancer. Advances in Oncobiology. (In Press) 1998.
22. Sakr WA, Macoska JA, Benson P, Benson DJ, Wolman SR, Pontes JE, and Crissman: Allelic loss in locally metastatic, multi-sampled prostate cancer. *Cancer Res.*, 54:3273-3277, 1994.
23. Mirchandani D, Zheng J, Miller GL, Ghosh AK, Shibata DK, Cote RJ and Roy-Burman P: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. *Am. J. Path.* 147:92-101, 1995.
24. Bauer JJ, Moul JW, and McLeod DG: CaP: Diagnosis, treatment, and experience at one tertiary medical center, 1989-1994. *Military Medicine*, 161:646-653, 1996.
25. Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC, McLeod DG, Srivastava S, Moul JW: Biostatistical modeling using traditional variables and genetic biomarkers predicting the risk of prostate cancer recurrence after radical prostatectomy. *Cancer*, 79:952-962, 1997.
26. Bauer JJ, Connelly RR, Sesterhenn IA, DeAusen JD, McLeod DG, Srivastava S, Moul JW: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk of disease recurrence after radical prostatectomy. *J. Urol.*, 159(3):929-933, 1998
27. Sager R: Expression genetics in cancer: Shifting the focus from DNA to RNA. *Proc Natl. Acad. Sci. USA*, 94:952-957, 1997
28. Strausberg RL, Dahl CA, and Klausner RD: New opportunities for uncovering the molecular basis of cancer. *Nature Genetics*, 15:415-16, 1997.
29. Liang, Peng, and Pardec AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257:967-971, 1992.
30. Velculescu VE, Zhang L, Vogelstein B, and Kinzler KW: Serial analysis of gene expression. *Science*, 270:484-487, 1995.
31. Chena M, Shalon DS, Davis RW, and Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarrays. *Science*, 270:467-470, 1995.
32. Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS and Hood L: Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer. *The Prostate* 30:145-153, 1997.

33. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhuang Z, Duray PH, Bostwick DG, Linehan WM, Liotta LA and Emmert-Buck MR: Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. *Urology*, 50:302-307, 1997.
34. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, and Russell DW: Increased expression of early growth response-1 messenger ribonucleic acid in prostate adenocarcinoma. *J. Urol.*, 155:975-981, 1996.
35. Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW and Pardee AB: Two differentially expressed genes in normal human prostate tissues and in carcinoma. *Cancer Res.*, 56:3634-3637, 1996.
36. Schleicher RL, Hunter SB, Zhang M, Zheng M, Tan W, Bandea CI, Fallon MT, Bostwick DG, and Varma VA: Neurofilament heavy chain-like messenger RNA and protein are present in benign prostate and down regulated in prostate carcinoma. *Cancer Res.*, 57:3532-3536, 1997.
37. O'Keefe, DS, Su, SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak, NJ, Shows, TB, Mullins, C, Vonder Haar RA, Fair WR, and Heston WD: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. *Biochim Biophys Acta*, 1443(1-2):113-127, 1998.
38. Silver DA, Pellicer I, Fair WR, Heston, WD, and Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin Cancer Res*, 3(1):81-85, 1997.
39. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, and Carter KC: A novel prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. *Genomics* 43(1):69-77, 1997.
40. Crespi MD, Jurkewitch E, Poiret M, d'Aubenton-Carafa Y, Petrovics G, Kondorosi E, and Kondorosi A: Enod 40, a gene expressed during nodule organogenesis, codes for a non-translatable RNA involved in plant growth. *The EMBO J* 13:5099-5112, 1994.
41. Velleca MA, Wallace MC and Merlie JP: A novel synapse-associated non-coding RNA. *Mol Cell Bio*. 14:7095-7104, 1994.
42. Takeda K, Ichijoh, Fujii M, Mochida Y, Saitoh M, Nishitoh H, Sampath TK and Miyazonok: Identification of a novel bone morphogenetic protein responsive gene that may function as non-coding RNA. *J. Biol. Chem.* 273:17079-17085, 1998.
43. Van de Sande K, Pawlowski K, Czaja I, Wieneke U, et al: Modification of phytohormone response by a peptide encode by ENOD 40 of legumes and a non-legume. *Science* 273:370-373.
44. Hao Y, Crenshaw T, Moulton T, Newcomb E and Tycko B: Tumor suppressor activity of H19RNA. *Nature*. 365:764-767, 1993.
45. Neumaier M, Gerhard M, Wagener C: Diagnosis of micrometastases by the amplification of tissue specific genes. *Gene*. 159(1) :43-47, 1995.
46. Gaddipati J, McLeod D, Sesterhenn I, Hussussian C, Tong Y, Seth P, Dracopoli N, Moul J and Srivastava S: Mutations of the p16 gene product are rare in prostate cancer. *The Prostate*. 30:188-194, 1997.

47. Davis LD, Sesterhenn IA, Moul JW and Srivastava S: Characterization of prostate cancer cells immortalized with E6/E7 genes. *Int. Symp. On Biol. Of Prost. Growth Proceedings*, National Institutes of Health., 77, 1998.
48. Wilkinson, D., & Green, J. (1990) in *Post implantation Mammalian Embryos*, eds. Copp, A.J. & Cokroft, D.L. (Oxford University Press, London), pp. 155-171.
49. Erdmann, V.A., Szymanski, M., Hochberg, A., de Groot, N., & Barciszewski, J. (1999) *Nucleic Acids Research* 27, 192-195.
50. Askew, D.S., & Xu, F. (1999) *Histol Histopatho.* 14, 235-241.
51. Bussemakers, M.J.H., Van Bokhoven, A., Verhaegh, G.W., Smit, F.P., Karthaus, H.F., Schalken, J.A., Debruyne, F.M., Ru, N., & Isaacs, W.B. (1999) *Cancer Res.* 59, 5975-5979.
52. Lanz, R.B., McKenna, N.J., Onate, S.A., Albrecht, U., Wong, J., Tsai, S.Y., Tsai, M.J., & O'Mally, B.W. (1999) *Cell* 97, 17-27.
53. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, and Srivastava S: PCGEM1: A Novel Prostate Specific Gene is Overexpressed in Prostate Cancer. Submitted to *Proceedings of the National Academy of Sciences*.

We claim:

1. An isolated nucleic acid molecule selected from:
  - (a) the polynucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8;
  - (b) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of (a) under conditions of moderate stringency in about 50% formamide and about 6X SSC at about 42°C with washing conditions of approximately 60°C, about 0.5X SSC, and about 0.1% SDS;
  - (c) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of (a) under conditions of high stringency in about 50% formamide and about 6X SSC, with washing conditions of approximately 68°C, about 0.2X SSC, and about 0.1% SDS;
  - (d) an isolated nucleic acid molecule derived by *in vitro* mutagenesis from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8;
  - (e) an isolated nucleic acid molecule degenerate from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:8, as a result of the genetic code; and
  - (f) an isolated nucleic acid molecule selected from the group consisting of human PCGEM1 DNA, an allelic variant of human PCGEM1 DNA, and a species homolog of PCGEM1 DNA.
2. A recombinant vector that directs the expression of the nucleic acid molecule of claim 1.
3. A host cell transfected or transduced with the vector of claim 2.
4. The host cell of claim 3 selected from bacterial cells, yeast cells, and animal cells.
5. An isolated nucleic acid molecule comprising the polynucleotide sequence selected from SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.
6. A method of detecting prostate cancer in a patient, the method comprising:

- (a) detecting PCGEM1 mRNA in a biological sample from the patient; and
- (b) correlating the amount of PCGEM1 mRNA in the sample with the presence of prostate cancer in the patient.

7. The method according to claim 6, wherein step (a) includes:

- (a) isolating RNA from the sample;
- (b) amplifying a PCGEM1 cDNA molecule;
- (c) incubating the PCGEM1 cDNA with the nucleic acid according to claim 1 or 5; and
- (d) detecting hybridization between the PCGEM1 cDNA and the nucleic acid.

8. The method according to claim 7, wherein the PCGEM1 cDNA is amplified with at least two nucleotide sequences selected from SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

9. The method according to claim 8, wherein the at least two nucleotide sequences are SEQ ID NO:15 and SEQ ID NO:22.

10. A method according to claim 6, wherein the biological sample is selected from blood, urine, and prostate tissue.

11. The method according to claim 10, wherein the biological sample is blood.

12. A vector, comprising a PCGEM1 promoter sequence operatively linked to a nucleotide sequence encoding a cytotoxic protein.

13. The vector of claim 12, wherein the PCGEM1 promoter sequence is a nucleic acid molecule comprising the polynucleotide sequence of SEQ ID NO:3.

14. A method of selectively killing a prostate cancer cell, the method comprising:

- (a) introducing the vector according to claim 12 to the prostate cancer cell under conditions sufficient to permit selective cell killing.

15. The method according to claim 14, wherein the cytotoxic protein is selected from ricin, abrin, diphtheria toxin, p53, thymidine kinase, tumor necrosis factor, cholera toxin, *Pseudomonas aeruginosa* exotoxin A, ribosomal inactivating proteins, and mycotoxins.

16. A method of identifying an androgen-responsive cell line, the method comprising:

- (a) obtaining a cell line suspected of being androgen responsive,
- (b) incubating the cell line with an androgen; and
- (c) detecting PCGEM1 mRNA in the cell line,


wherein an increase in PCGEM1 mRNA, as compared to an untreated cell line, correlates with the cell line being androgen responsive.

17. A method of measuring the responsiveness of a prostate tissue to hormone-ablation therapy, the method comprising:



- (a) treating the prostate tissue with hormone ablation therapy; and
- (b) measuring PCGEM1 mRNA in the prostate tissue following hormone ablation therapy,

wherein a decrease in PCGEM1 mRNA, as compared to an untreated cell line, correlates with the prostate tissue responding to hormone ablation therapy.

1/21


STRATEGY FOR THE IDENTIFICATION OF  
GENE EXPRESSION ALTERATIONS  
IN PROSTATE CANCER**FIG. 1****SUBSTITUTE SHEET (RULE 26)**


2/21

**FIG. 2****FIG. 3**

SUBSTITUTE SHEET (RULE 26)


3/21

**FIG. 4****SUBSTITUTE SHEET (RULE 26)**



**FIG. 5A**

5/21



**FIG. 5B**

SUBSTITUTE SHEET (RULE 26)

6/21





FIG. 6A

SUBSTITUTE SHEET (RULE 26)


whole brain	amygdala	caudate nucleus	coro- billum	cerebral cortex	frontal lobe	hippo- campus	medulla oblongata
occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	nucleus accumbens	spinal cord	
heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
appendix	lung	trachea	placenta				
fetal brain	fetal heart	fetal kidney	fetal liver	fetal spleen	fetal thymus	fetal lung	
yeast total RNA 100 ng	yeast RNA 100 ng	E. coli RNA 100 ng	E. coli DNA 100 ng	Poly r(A) 100 ng	human CpG DNA 100 ng	human DNA 100 ng	human DNA 500 ng

# FIG. 6B

SUBSTITUTE SHEET (RULE 26)



**FIG. 7A**



**FIG. 7B**

SUBSTITUTE SHEET (RULE 26)

9/21

cDNA sequence of PCGEM1 Sea.ID No .1

AAGGCACTCT	GGCACCCAGT	TTTGGAACTG	CAGTTTAAA	AGTCATAAAT	TGAATGAAAA	TGATAGCAAA	70
GGTGGAGGTT	TTTAAAGAGC	TATTTATAGG	TCCCTGGACA	GCATCTTTT	TCAATTAGGC	AGCAACCTTT	140
TTGCCCTATG	CCGTAACCTG	TGTCTGCAAC	TTCCTCTAAT	TGGGAAATAG	TTAAGCAGAT	TCATAGAGCT	210
GAATGATAAA	ATTGTACTAC	GAGATGCACT	GGGACTCAAC	GTGACCTTAT	CAAGTGAGCA	GGCTTGGTGC	280
ATTTGACACT	TCATGATATC	ATCCAAAGTG	GAACTAAAAAA	CAGCTCCTGG	AAGAGGACTA	TGACATCATC	350
AGGTTGGGAG	TCTCCAGGGA	CAGCGGACCC	TTTGGAAAAG	GAATAGAAAG	TGTGAAATCT	ATTAGTCTTC	420
GATATGAAAT	TCTCTGTCTC	TGTAAAAGCA	TTTCATATTT	ACAAGACACA	GGCCTACTCC	TAGGGCAGCA	490
AAAAGTGGCA	ACAGGCAAGC	AGAGGGAAAAA	GAGATCATGA	GGCATTTCAG	AGTGCACTGT	CTTTTCATAT	560
ATTTCTCAAT	GCCGTATGTT	TGTTTTTATT	TTGGCCAAGC	ATAACAATCT	GCTCAAGAAA	AAAAAATCTG	630
GAGAAAACAA	AGGTGCCCTT	GCCAATGTTA	TGTTTCTTTT	TGACAAGCCC	TGAGATTCT	GAGGGGAATT	700
CACATAAATG	GGATCAGGTC	ATTCAATTAC	GTTGTGTGCA	AATATGATTT	AAAGATACAA	CCTTTGCAGA	770
GAGCATGCTT	TCCTAAGGGT	AGGCACGTGG	AGGACTAAGG	GTAAAGCATT	CTTCAAGATC	AGTTAATCAA	840
GAAAGGTGCT	CTTTGCATTC	TGAAATGCC	TTGTTGAAA	TATTGGTTAT	ATTGATTAAA	TTTACACTTA	910
ATGGAAACAA	CCTTTAACTT	ACAGATGAAC	AAACCCACAA	AAGCAAAAAAA	TCAAAAGCCC	TACCTATGAT	980
TTCATATTTT	CTGTGTAAC	GGATTAAAGG	ATTCTGCTT	GCTTTGGC	ATAATGATA	ATGGAATATT	1050
TCCAGGTATT	GTTTAAATG	AGGGCCCATC	TACAAATTCT	TAGCAAACT	TTGGATAATT	CTAAAATTCA	1120
GCTGGACATT	GTCTAATTGT	TTTTATATA	CATCTTGCT	AGAATTCAA	ATTTTAAGTA	TGTGAATTAA	1190
GTAAATTAGC	TGTGCTGATC	AATTCAAAAAA	CATTACTTTC	CTAAATTAA	GAATGAAAG	GTCATAAATT	1260
CAACAAATAT	ATCTACACAT	ACAATTATAG	ATTGTTTTTC	ATTATAATGT	CTTCATCTTA	ACAGAATTGT	1330
CTTTGTGATT	GTTTTAGAA	AACTGAGAGT	TTTAATTCTAT	AATTACTTGA	TCAAAAATT	GTGGGAACAA	1400
TCCAGCATT	ATTGTATGTG	ATTGTTTTTA	TGTACATAAG	GAGTCTTAAG	CTTGGTGCCT	TGAAGTCTTT	1470
TGTACTTAGT	CCCATGTTA	AAATTACTAC	TTTATATCTA	AAGCATTAT	GTTTTCAAT	TCAATTACAA	1540
TGATGCTAAT	TATGGCAATT	ATAACAAATA	TTAAAGATTT	CGAAATAGAA	AAAAAA	AAA	1603

**FIG. 8****SUBSTITUTE SHEET (RULE 26)**


10/21

cDNA sequence of PCGEM1 Sea. ID No. 2

GCGGCCGCGT CGACGCACT TCCTCTAATT GGGAAATAGT TAAGCAGATT CATAGAGCTG AATGATAAAA 70  
 TTGTACTTCG AGATGCACTG GGACTCAACG TGACCTTATC AAGTGAGATG GAGTCTTGCC CTGTCTCAA 140  
 GGCTGGAGCC CAATGGTGTG ATCTTGGCTC ACTGCAACCT CCACCTCCCA GGTCAAACG TTTCTCTGC 210  
 CTCAGCCTCC CAAGTAACTG GGATTACAGC AGGCTTGGTG CATTGACAC TTCATGATAT CAGCCAAAGT 280  
 GGAACTAAAA ACAGCTCCTG GAAGAGGACT ATGACATCAT CAGGTTGGGA GTCTCCAGGG ACAGCGGACC 350  
 CTTTGGAAAA GGACTAGAAA GTGTGAAATC TATTAGTCTT CGATATGAAA TTCTCTGTCT CCGTAAAGC 420  
 ATTTCATATT TACAAGACAC AGGCCTACTC CTAGGGCAGC AAAAAGTGGC AACAGGCAAG CAGAGGGAAA 490  
 AGAGATCATG AGGCATTCA GAGTGCACTG TCTTTCTATA TATTCTCAA TGCCGTATGT TTGGTTTTAT 560  
 TTTGGCCAAG CATAACAATC TGCTCAAAAA AAAAAAAATCT GGAGAAAACA AAGGTGCCTT TGCAATGTT 630  
 ATGTTTCTTT TTGACAAGCC CTGAGATTTC TGAGGGGAAT TCACATAAT GGGATCAGGT CATTCAATT 700  
 CGTTGTGTGC AAATATGATT TAAAGATACA ACCTTTGCAG AGAGCATGCT TTCTTAAGGG TAGGCACGTG 770  
 GAGGACTAAG GGTAAAGCAT TCTTCAAGAT CAGTTAATCA AGAAAGGTGC TCTTGCATT CTGAAATGCC 840  
 CTTGTTGCAA ATATTGGTTA TATTGATTAA ATTTACACTT AATGAAACA ACCTTTAATC TACAGATGAA 910  
 CAAACCCAC AAAAGCAAAA AATCAAAAGC CCTACCTATG ATTCATATT TTCTGTGTAA CTGGATTAAA 980  
 GGATTCTGC TTGCTTTGG GCATAAAATGA TAATGGAATA TTTCCAGGT TAATGTTAAA TGAGGGCCA 1050  
 TCTACAAATT CTTAGCAATA CTTTGGATAA TTCTAAATT CAGCTGGACA TTGTCTAATT GTTTTTATA 1120  
 TACATCTTG CTAGAATTTC AAATTTAAG TATGTGAATT TAGTTAATT GCTGTGCTGA TCAATTCAA 1190  
 AACATTACTT TCCTAAATT TAGACTATGA AGGTCAAAAA TTCAACAAAT ATATCTACAC ATACAATTAT 1260  
 AGATTGTTT TCATTATAAT GTCTTCATCT TAACAGAATT GTCTTGTGA TTGTTTTAG AAAACTGAGA 1330  
 GTTTTAATTCA ATAATTACTT GATCAAAAAA TTGTGGAAC AATCCAGCAT TAATTGTATG TGATTGTTT 1400  
 TATGTACATA AGGAGTCTTA AGCTTGGTGC CTTGAAGTCT TTTGTACTTA GTCCCATGTT TAAAATTACT 1470  
 ACTTTATATC TAAAGCATTT ATGTTTTCA ATTCAATTCA CATGATGCTA ATTATGGCAA TTATAACAAA 1540  
 TATTAAAGAT TTCGAAATAG AAAAAAAA AAAAATCTA 1579

**FIG. 9****SUBSTITUTE SHEET (RULE 26)**

11/21

**FIG. 10****SUBSTITUTE SHEET (RULE 26)**

12/21

cDNA sequence of PCGEM1 Promoter Region Seq.ID No.3

TCCCTCTTGC GTTCTGCAAT TTCTGAAAAA AAGATGTTA TTGCAAAGTG ATATGAGCAC TGGAAAGGTA 70  
 CTAATTCCAA TTTGATTCTA ATTGGATGAG TGACATGGGT AAGCGATTCT AAGCATTGT GTTTTTTTA 140  
 GTAGTATGGA ATTTAATTAG TTCTCAGTAT GTTAGTGAAG ATGAATGAAA ACATGCATAT GTTTCATGT 210  
 ATTATAAATA TTTTAAATG CAAAAAATTA TTCTAATGAA TATATAAATA TAAAGCATAA CAATAATAAT 280  
 ACAATACAC CCATAAAGTC ATCATCTAAT TTAAAAACTA AAACATTAAC ACTTGAATCT CCCCCATTGC 350  
 AACATCTTC CCGACTTGTG TGTTTTTTTC TTGCTTTT AAAATTTTG TTTTATCATA TGTCTGCATA 420  
 AGATTATATA GCTTCCTTG TTTAAGCTT TTTAAATAAT ATATTGTAGT TATATTATTG GTGCTTGCT 490  
 TTTTTACTT AACATTATGG TTCTAAAATT CAGTAATGTG TTGGCATGT ATAATTGTT TATTTTAAT 560  
 CTCTTGACA TTCGACTATA TAAATTCAG TTGTTTATT GACTCCTTG TCTATAGATA CTCTGCTATT 630  
 TCTGTTTTTG CTGTTACAAA AATAATGCTG TTTAAATT CATTGTAT ACTTTTTGA GGCATGTGTA 700  
 TGAGTTATTC TAAGGAAAA AAATAAGAAA AAATTGCTGG GTTATAAGAT TGTCACATGC TCGAATTAC 770  
 AAGATAATGC CAAATCATT TTCAAAGTAA TTACACCTAT TTACTTACCC GGTATGAGTA TATTGGTGCC 840  
 CACATAGTTG CTTGTTCTGC CAAAGTTGG TATGATCGAA CAATAATTG TGCCCATCAA ATGGCATAAA 910  
 ATAAAATCTC AGTGTGCTTT TAATTGCAAT TTCTATGTT TAAGAATTGT TTCTTTTTA ACCATTATA 980  
 ATTTACTTTT GCTGAAATGC TTGCTTATTA TTTTGCTCC CCATTTTTTC CTATTGGATT GCTTTCTCA 1050  
 TTAATTATA AGAATTTTAT ATGGTTAGA TACTAATTAT TATATTACTG AAAATACCTT TATCAGTTG 1120  
 TTGTTGACTT TCTACTTTAT GTCTTGTGAT GGATAAAAGT TTTAAATTGT ATTGTGTTGA AGTTAACATT 1190  
 TTTAAATT TATAATCAGCA TCTTTAATAA TCTCTTMTA AAATTTCCT TTACATAGAT GTCATAAAGA 1260  
 TACATCTCTA TAATTCTTA TTTTTTGCG ATATGTCAT TAAGTCATTT TATCATTAA TAGTAATAAA 1330  
 TTGCAATTAT TTATGAAACA AATAATT TTTTAAATTAT ATGCTTCTT TAAAAATTGA TCTTACCATG 1400  
 CTTCACTATG AAGCTTGAGG CTTCACTGCA CGTTGTACTG AAATTATGTA TAAAACAGTG GTTCTGAAAA 1470  
 TCTCTGAGTT CATGACACCT TTAGTGTCTC AGGTTTTT GCTTTGTTC TTGTTTTTC TCACAAAGCA 1540  
 CCTAAGTTAA ATAAAAACAA AGCACAAAGC TATCAGCTTC ATGTATTAAG TAGTAAGCTC CCATGTTAAC 1610  
 AGTTGTAAC TGCCTGGTGC CCAATAGATG TCACCTGTT TTCTAGAAA CTTTAAATA TCCCTCAGTG 1680  
 CTCCCTGTTAA TTCATGGTAG TGCCCCAAGG CACTCTGGCA CCCAGTTTG GAACTGCAGT TTTAAAGTC 1750  
 ATAAATTGAA TGAAAATGAT AGCAAAGGTG GAGGTTTTA AAGAGCTATT TATAGGTCCC TGGACAGCA 1819

**FIG. 11****SUBSTITUTE SHEET (RULE 26)**

cDNA sequence of PCGEM1 PROBE Seq.ID No.4

TTTTTTCAAT TAGGCAGCAA CCTTTTGCC CTATGCCGT A CCTGTGTCT GCAACTTCCT CTAATTGGGA	70
AATAGTTAAG CAGATTCATA GAGCTGAATG ATAAAATTGT ACTACGAGAT GCACTGGGAC TCAACGTGAC	140
CTTATCAAGT GAGCAGGCTT GGTGCATTG ACACCTCATG ATATCATCCA AAGTGGAACT AAAAACAGCT	210
CCTGGAAGAG GACTATGACA TCATCAGGTT GGGAGTCTCC AGGGACAGCG GACCCTTGG AAAAGGACTA	280
GAAAGTGTGA AATCTATTAG TCTTCGATAT GAAATTCTCT GTCTCTGTAA AAGCATTCA TATTTACAAG	350
ACACAGGCCT ACTCCTAGGG CAGCAAAAG TGGCAACAGG CAAGCAGAGG GAAAAGAGAT CATGAGGCAT	420
TTCAGAGTGC ACTGTCTTT CATATATTTC TCAATGCCGT ATGTTTGGTT TTATTTGGC CAAGCATAAC	490
AATCTGCTCA AGAAAAAAA ATCTGGAGAA AACAAAGGTG CCTTGCCAA TGTTATGTT CTTTTGACA	560
AGCCCTGAGA TTTCTGAGGG GAATTCACAT AAATGGATC AGGTCAATTCA TTTACGTTGT GTGCAAATAT	630
GATTTAAAGA TACAACCTTT GCAGAGAGCA TGCTTCCTA AGGGTAGGCA CGTGGAGGAC TAAGGGTAAA	700
GCATTCTTCA AGATCAGTTA ATCAAGAAAG GTGCTCTTG CATTCTGAAA TGCCCTTGTGTT GCAAATATTG	770
GTTATATTGA TTAAATTTAC ACTTAATGGA AACAAACCTT AACTTACAGA TGAACAAACC CACAAAAGCA	840
AAAAATCAAAGGCCCTACCT ATGATTTCAT ATTTCTGTG TAACTGGATT AAAGGATTCC TGCTTGCTTT	910
TGGGCATAAA TGATAATGGA ATATTCAG GTATTGTTA AAATGAGGGC CCATCTACAA ATTCTTAGCA	980
ATACTTTGGA TAATTCTAAA ATTCAGCTGG ACATTGTCTA ATTGT	1025

**FIG. 12**

14/21

PCGEM1 Primers Used for PCRPCR PRIMER 1 (SEQ ID No.5)

Sense Primer 5' TGCCTCAGCCTCCCAAGTAAC 3'

PCR PRIMER 2 (SEQ ID No.6)

Antisense Primers 5' GGCCAAAATAAAACCAAACAT 3'

PCR PRIMER 3 (SEQ ID No.7)

Sense Primer 5' TGGCAACAGGCAAGCAGAG 3'

**FIG. 13****SUBSTITUTE SHEET (RULE 26)**

15/21

Complete Genomic DNA sequence of PCGEM1 gene.

TCCCTCTGCGTTCTGCAATTCTGAAAAAAAGATGTTATTGAAAGTGATATGAGCACTGGAAAGGTACTAATTCAA  
 TTTGATTCTAATTGGATGAGTGACATGGGTAAAGCGATTCTAACGATTGTTTTTTAGTAGTATGGAATTAAATTAG  
 TTCTCAGTATGTTAGTGAAGATGAATGAAAACATGCATATGTTCCATGTTATAAAATTAAATTGCAAAAAATTAA  
 TTCTAATGAATATATAAATATAAACATAACAATAATACAAATACCACCCATAAAGTCATCATCTAACATTAAACTA  
 AAACATTAACACTGAACTCCCCATTGCAACATCTTCCGACTGTGTTTTCTTTGCTTTAAATTTTG  
 TTTTATCATATGTCGATAAGATTATAGCTTCTGTTAACGTTTTAAATAATATTGAGTTATTTAAT  
 GTGCTTGTCTTTTACTAACATTATGGTCTAAAATTCACTAATGTTGGCATGTATAATTGTTATTAAAT  
 CTCTTGACATTGACTATATAAATTCACTGTTGTTATTGACTCCTTGTCTACATACACTCTGCTATTCTGTTTG  
 CTGTTACAAAATAATGCTGTTAAATTCACTTGTATACTTTTGAGGCATGTATGAGTTATTCTAACGTA  
 AAATAAGAAAAAATTGCTGGGTTATAAGATGTCACATGCTGAATTACAAGATAATGCCAATCATTTCAGA  
 TTATACCTATTATACTACCGGTATGAGTTATTGGTCCCACATAGTGCTTGTCTGCCAAGTTGGTATGATGAA  
 CAATAATTGGCCATCAAATGCCATAAAATAAAATCTCAGTGCTTTAAATTGCAATTCTATGTTAAGAATTG  
 TTCTTTTAAACCATTATAATTACTTTGCTGAAATGCTGCTTATTATTGGCTCCCCATTTCCTATTGATT  
 GCTTTCTCATTAATTATAAGAATTGTTAGACTAATTATTACTGAAACACCTTATCAGTT  
 TTGTTGACTTTCTACTTTATGCTTGTGATGGATAAAAGTTAAATTGATTGCTTGAAGTTAACATTAAATT  
 ATAATCAGCATCTTAATAATCTCTTATAAAATTTCCTTACATAGATGTCATAAACATCCTATAATTCTTA  
 TTTTTGGCATATGTCATTAAGTCATTATTTAGTAATAATTGCACTTAAATTGAGTTATTGAAACAAATAATT  
 AAAATTATATGCTTCTTAAATTGATCTAGCATGCTTCACTATGAAAGCTTGAGGCTTCACTGCACGTTGACTG  
 TTGTTTTGTCACAAAGCACCTAAGTTAAATTAAACAAAGCACAAAGCTATCAGCTCATGTATAAGTAGAAGCTC  
 CCATGTTAACAGTGTAACTTGCTGGTGCCTGCCAATAGATGTCACTCTGTTCTAGAAACATTAAATCCCTCAGTG  
 CTCTGTTAACATGCTGGTACTGGCCAGGCACTCTGGCACCCAGTTGGAACTGCAGTTAAAGTCATAATTGAA  
 TGAAAATGATAGCAAAGGTGGAGGTTAAAGAGCTATTATACCTCCCTGGACAGCATTTTCATTAGGCAGCA  
 ACCTTTTGCCATGCCGTAAGTGTCTGACTTCCTCTAATTGGGTGAGTAAGAGATTGTTATGTTATATAATTAGC  
 TAAGAATATAGTAATAATCCCTTAATCATGGTTATTAAACTACTAACATTAGAAGACAAAATAATTGCTTGA  
 AAAGTATAGAGGTTTACTGTAATTAGCAGGGATAATGAAATGATTGATAGGGCTACTCAGTTGTTATAACTTGGT  
 GCTTTAAGTCTGAATGCAAGAGCATGGATGTTGATCCAGCCTTATATGTTTCCCTGAAGAAGATTAAATTG  
 CCTTTGAGAAACACATTGGCATTGTAATTGTTGCTTCCAGGTCTATCTCAAGGATAATTGACAAATCACAC  
 ATAAATTATTTCAGGGCACACAGTTCCCTTTAGGAAACTCACAGAGTAGAGAGTAATAACATAATCACATTGAA  
 TATTCAAGTGAAGTGGCTCATAGATCTTATGTTATGTCACCATGTATATAATTGTTAATCAGATGTTGAGA  
 CAAGAAATTGAGGAATCTTAACTAGAGATTAAACAGGGATTAAATCAAAGAAACATTAAATGCCTCCTTATTAT  
 TTAAATACCTGCATGGGAGAATCTGAAAAAAATAAAAGCATACAACATTGGGAATTATATAACCAAGAAGAATT  
 GTTATTCTGGTTGATTTTTCAAGGCTCCGACAGGCAACTACCTTATCTCTTGTGATTATTCTTGTAA  
 ATATAACAGAAATGTTAAGCAGATTGAGCTGAATATAAAATTACTACAGAGATGCACTGGGACTCAACGTGACCTT  
 ATCAAGTGAATTCACTGAGGTGAGCATTCTTAATTCACTAATGAACTTATTATCATAATCTTGTCTTATGCTATT  
 GTTGAGCTTAACACTTATTGATATGCAATTGAGATAATTGTTATTAATTTCAGTACTGAAACACTAA  
 TCTCCTAAGAGTAATTGAAAGTTCACTGACTATTAACTATATCTGTTGTTATCTTCAATTGCTGAA  
 ATAACATTATAAGCAATTGAAACATTCAATTACAGTATACTATTGAGCAAATCAACAAATATAACACATATCCATTAGC  
 AATAGTAGATAATTGTTAATGTCAGCACAGTCTTCAATTGAGGAGTGTCAAATTGGCTAAGTTCCCTTCTC  
 TCTTAATTATTAGTATTTCCTACTGCTTTGTATAATTATTCTTCTTGTAAATTGCTTCAATTCTACATTCT

**FIG. 14**

SUBSTITUTE SHEET (RULE 26)

16/21

TAACATAGCAACTGGGAAGAAAGTTTAAACATAAACCAGATGATGTCACTCCACCCCACAAAACCTCCACTATTCTCT  
 GTCACACATAGAAAGAAAAAAATATTGAAAACCTACAAAGACTTGTATGATCTGGCTCAGGCTCCCTAAAT  
 TTCACTGTAATTCCAGCCACTAGGCCTTCTGGCTCTCCTCAATCTCATTAGCCTTTCACTACTACAAGTTAGACTGG  
 GTTTGGCCGAGGTATTCTTTTCAATTTCGCTTGCCTAGATTGCTCTCCAATAGATAATTACAATTGCATCA  
 TCATTCTATACGTCTAAAAGGTTCTGTCCAAATAGCTTCACTGACCACCTGATCTAGAATAGTCTCGATCAA  
 AAGTTCTTTCCCTTCACCACCTGATATTATACAAACATTATTGTGTAATTATGTGTTGTTCT  
 GTACTAGCATTATGATGACCACACTATTGATGCCCAAAAAACTTTCGAGAATGACAGGGAAAGCTAAAATAAT  
 TAAATTATATAATTGACATAGGCACATTGACAAAAGCAATTGATGTTATGATAGTGTAGATCTATGAAATAGTAC  
 TATTAAAAGTAATTCTGAAATACAATTCTAAACTAAAAGCAGCATAATGTACATGAAACACCAAAAAACTCCCT  
 ATATTATCACTGGAAGATTAAAATAGTATAAGTAACTTATTAAATATTGATTATTAAATTAAATTATAG  
 TATCCAACCTCTAATATAATGCCACTGGTATTGTTCAAATATTAAATGTTCTATTATTAAATTGCTAAAAA  
 TTATCTTAAATGAAAATTGGTAATAAAATTGAAAATCTGAAACCTCATCTCAGTCTGTGGATCCTAAAGTT  
 TTAGTTGAGAAAATAATTCTCTAGAGAATGAAGTAGCTTGTAAAGCTTGGAGAAATTCTGCTAAATAATGATATT  
 ATCAACTCTTATTCTCAATACGAAATATAATTTCAGCTCATATTGTCAGGTGCTATGCTTGTCC  
 AATCATAATTCTGACAAATATTGGAAGTCAAAACTTGTCTCTATTGTTATTAAAATTATAGACTACTTTG  
 TAAACCTTATACTATCAAATCATAGGCAATTTCAGTTGATTCTGGTGCAGAATATAAGTTATCCAAGTAAAA  
 CAGGAGTCACCTCAAAAGATTCCCTCCACTGACTGAGATATTCCAAGCCAACCTTGCACAAATTCTAGAATTAAATATT  
 TACTTCTTGTACCTCATTATTGTTCAATTTCCTTGTGTTGAGAAAATTAAATATTCTGTGTTCAAGT  
 TTGATTTAATTACTACTTTATAATTAAAGTAAGTTGAGGCTATTCAATTGTTGTTGAATAAGAC  
 ATACAATTAAATTGAGAACTGCAATAAAATTATAAGACTATTAAAATGCAAGTGTACTACACTTAGGCTGCTAA  
 AAATGCACTACAGTAGACTACATTAGGCTGCTAAAGTTAGCTCTCAAGTACCATATACTTAAATTAGCTAA  
 TGATGGAGAACAAAGACAGAAAGACTGTTACCATATTCTAGTGGCATTGTTGAGAGACGTCACATCA  
 GCCTTATCATAAAATTATTGTTTACCATTTGACTGTGAGCAAAATACAGCATAATACAAAATAACAT  
 GTACATCTCACAACCTCTGTTAGGATGCAATTATATATATATATATTATTATTAAATTCTGTTCTA  
 GGGTACATGGCACCACGTGCAGGTGTTACATGTATACATGTGCCATTGGTGTGCTGCCACCAATTACTGTCATT  
 TACATTAGGTGTATCTCTAATGCTATCCCTCCCTCTCTCCCCACCCACAACAAGCCGGTGTGATGTTCCCTT  
 CCTGTGTCATGTGTTCTCAATTCCCACCTATGAGTGAGAACACGCACTGTTGCTTTGTTGCAATA  
 GTTTGTCAGGATGATGGTTCCAGCTTCAATTGCTACAAAGGACATGAACTCATCATTGTTATGGCTGCATAG  
 TATTCCATGGTGTATATGTGCCACCATTTCTTAATCGAGTCTGTCATTGTTGGACATTGGGTTGCAATTGGA  
 GTCTTGCTGTCTCCAGGCTGGAGCCAAAGGTGTGATCTGGCTACTGCAACCTCCACCTCCGGTCAAGCGATT  
 CTCTGCCCTCAGCCATCCGAGTAGCTGGACTATAGGCGTGCACCACCATGCCAGCTAATTGTTGTTAGTACAG  
 ACGGGTTTACCCACGGTGGCCAGGATGGTCAATTCTGACCTCATGATTCAACCCGCTTGGCTCCAAAGTGTG  
 GGATTACAGGTGTGAACCACCAAGCCGGCCTGTCACAAGTTTACTGTTCTATTAAATACAGAAATTAGATAAAATCC  
 AAACAGAAAGACATTCTATGTGCGTAGACTGTCAGGAAAGTAAACAGAGTCTTAAATACTTAAATTGTAAGA  
 AATAAAGGCAAAATAGCCTATGCACTTGTATTAAATATTCTTAATAAGAGCTACTTGTGAAACCAGAATAATTG  
 AAACATGTAGATATGGATCTCATAGTACTGACATAATATTGTTATGTGTTACTATTGTTATGTGATCAGCCA  
 ATTGACTGCTTGTGATCCTAAGCACTATGCTAAACACTGTACAGTATTACCTGATATAATCATATTAAATTATT

**FIG. 14(cont'd-1)**

17/21

ATTTCACTTTCATATGAAAAAATTGAAAGCACAGACATTAAGACACTCCGAAATCATACCTCTATTGATTATCAGCACCAGG  
 ATTTGAATTGAGGCACCTGATCCAGAGCTTGTTCATGAAGGCTTATGTTGGGAAAAATAATCAAATTGCCT  
 GTACCTCAGTTGTATAAATAAGAGGTTGGTTGGTAGATGATTCTGGCTGATTCAAGCAGAAAAGAAATTATTCAAAGGA  
 TATCACACAGTTCTATAACAGTTAAGAATACAGAGGAAACAGGGCACCAAGGGCTAAGTACAGACCAAAGTCCAAACCA  
 CTGCCAAAGTTGCAGCAAGGAGAACAGCACAAATTGCTTGCTCACCCGCCTAGATGCTTTGTTGGAGCCTG  
 ACTTGACTTACACTGCCACTGACATCAGCACCAGTGCTCTGTACTAGGAGGTTGGAGCTTGCTGA  
 AAAGCAGATGTTCTGCTGTGAAATAGATACCTAATACAGAACCTGATTCTCATTCCCTCCCCAATCATATGCT  
 TGTAGTGTGGCTAGAGTTCTGTTCTCCTGGCCAGGCAGAATTATGAGCTTGCTATTATGCCCTAAAGATTAG  
 AAGAATATTCAAGGTATTAGATTGCCATAAGGTTGAACAAATCAACATTCAACTCAAGGATTCAACATTGTTGTT  
 TTCTTTGGATACCTCTGCAGCTCAAATCTTATTCTGCCCTGGACAACCAGGTTATAAATTGAGATCTC  
 CACTGACTGCTTGTACTCTATCTCTATATTGTACTAATTAGCATATAAAGGATTATGTTACAGAACATCTCAA  
 AATTAGTAATTATGAATTGAGATGGTGTACAGTACACTAACATCCAAGAGACTTGTATTCCAAGGAAAATTTTA  
 GAGATATTAAATGATATTCTCATCCTTAGACATATACATTAGCTACAGCCTGTTAGGCAAGAACAGACTC  
 TCAGGATCTGCTCCTACAGGGCTGAACATTCTCCAGTTAAAGAAACAAATTCAAATAACATTGTAACCTCCAG  
 AGGAAAGTCAAGGCTTTATAGTATTGTTAAACAGTACAGCTGAGGAAACTAAAGACAGAGAACTTAAATGCCCTGG  
 CACTTAGTCTAGATTACAATAACTCCYTCTACTTAGGACCCACTAACAGGGCTGCATTACACCAAAACATGAAG  
 GTGGCCCAAGTCATCACTGAGAAGTAGTACAAGCACCGAGGGATGACTCAACAGGAACAAGAACGTGGAAGGAGAT  
 CCTAGCAGGAAGCTCCACAAGAACATAGCATGTTACGTCTGCTTGGATGAAGCAGGTTAGAGAGACCTAGTGACAGC  
 TATCTCCGTCAAGGTGAGAAGGAGATCATTGAATGTAGCATTTCATGCAAAAAAAATGTTGAAGTCTTGGAC  
 TTCGGGAGTCTGCCAACTGCAGGTCACTCAGCCTACAGTGGGATGAATTCTAAACACCAGTTGGAGCCGGTGAAT  
 CTTTCTGCTATGCTGAATATTTCAGTAAACCCAGCGAACAAACAACAAAACACAAAAGGAGGAGAACGCCAAG  
 TCTCTGGTTACAGAGTAGCTCTAAACCCCTGCTGCTCAAGTGCCTAATGGGAAGATAGTCAAAACAATAT  
 TCACACCTGTGATTCTCTCATGCACTGAGTGTGTGAATTCTTATATCTGCAATTAAAGGATCTGCTTACAGAT  
 AAAACTAAAGCATTGAAGGAACCTCTGTTGACTTATCAAAGTCCTAAGAAAATACTAGAAAATTAGCCATTGT  
 TTCAAATTCTAGCTTATATTACTTGAAATGTGATGAAATGTGGCTGATAGATAATAATTCACTGATAACCTACAGA  
 CAATTCCCATCTTAAATGGACCATTGGATTGAAGAATTAAATAATTGAGGTTTCCATGTTGTCTAAAGA  
 GCGAAGTAGAAACAACCTGTTCATAGATCTCATTGAGGATTGCGATGTGAAGTAAGTACTCCTAACATAAACAGTGGAC  
 TTATCAACCAAGTCCATAATCATGAACAAAATTTGCTCCAGAGAGACTATTTCACCACTCTTGTAA  
 AACACAGAGCCCAGTTCAAGTTAAACTTTAAGGGTGGACGGTCAAGGGCTGCTGAGTGGCACTCAGTAAGAAAACCC  
 AGCAGAACATTACTCTCTTATTCCAGAGCATCAATGCCAACGGCTGGAAGATCCCAGAACACTGAACAGACATT  
 GGTCTCTTATGGCCTGCCAATTTCACAGTGGCTCCAAACGCTTGGGTCAAACAAAATAGACCTGTTAGAAAATGTC  
 GGTTGGAAATCGCTAACATAAGACAGAATAATGTGATTATTCACTCATTGTTATAGGACTTGAGTAATTCTATT  
 AACATTCTGAGGGCTGAAAATCTGAATGTTAGGACACCAAATATCTCAGAAAACAAGTTTATATTCTAATCCTGC  
 ATAATAAACCTGGGGCACTGCAGGCCTATTAAATAAAACCTAATGGTATAACAATAATGAGGAGGAATGCCAATGCC  
 GCACAAATCTGTTGAGACTAAAATATTCTCACCCAGCAGGCTGGTCAATTGACACTTCATGATATCAGCCAAAGTG  
 GAACTAAAACAGCTCTGGAGAGGACTATGACATCATCAGGTTGGAGTCTCCAGGGACAGCGGACCCCTTGGAAAAG  
 GACTAGAAAAGTGTGAAATCTATTAGCTCTGATATGAAATTCTCTGCTCTGCTAAAGCATTCTAATTACAAGACAC  
 AGGCCTACTCCTAGGGCAGCAAAAGTGGCACAGGGCAAGCAGAGGAAAAGAGATCATGAGGCAATTCAAGACTG

## FIG. 14(cont'd-2)

18/21

TCTTTCATATTTCTCAATGCCGTATGTTGGTTTATTTGGCAAGCATAACAATCTGCTCAAGAAAAAAATCT  
 GGAGAAAACAAAGGTGCCTTGCAATGTTATGTTCTTTGACAAGCCCTGAGATTCTGAGGGGAATTACACATAAAAT  
 GGGATCAGGTCAATTACGTGTGCAAATATGATTAAAGATAACACCTTGAGAGAGCATGCTTCCTAAGGG  
 TAGGCACGTGGAGGACTAAGGTAAGCATTCTCAAGAATCAGTTAATCAAAGAAAGGTGCTTTGCAATTGAAATG  
 CCCTGTTGCAAATATGGTTATTTGATTAAATTACACTTAATGAAACAACCTTAACAGATGAACAAACCCA  
 CAAAAGCAAAAAGCAAAGCCCCACCTATGATTCAATTCTGTAACGGATTAAAGGATTCTGCTTGCTTTG  
 GGCATAAAATGATAATGGAATATTCCAGGTATTGTTAAATGAGGGCCATCTACAAATTCTAGCAAAATTTGGATA  
 ATTCTAAAATTCACTGGACATTGCTAATTGTTTATATACATCTTGCTAGAATTCAAATTAAAGTATGTGAAT  
 TTAGTTAATTAGCTGTGCTGATCAATTCAAACATTACTTTCTAAATTAGACTATGAAGTCATAAAATTCAACAAA  
 TATATCTACACATAATTAGATGTTTCAATTACGTGATCAAATTGTGGAACATCCAGCATTAAATTGTATGTGATTGTT  
 GAAAACGTGAGAGTTAATTCAATTACGTGATCAAATTGTGGAACATCCAGCATTAAATTGTATGTGATTGTT  
 TTTATGTACATAAGGAGCTTAAGCTGGTGCCTGAGTCTTTGTAATTAGCTCCATGTTAAATTACTACTTTATA  
 TCTAAAGCATTATGTTTCAATTCAATTACATGATGCTAATTATGGCAATTATAACAAATTAAAGATTCGAAAT  
 AGAATATGTGAATTGTCACCATACATAGAAATGAAAGCTCATTCGAAAGCAAGATGCTGGTGAAAGAGTGCTTT  
 GATTGAAAGATCACTAGATTAGTAGAGGGCAAGACTTTAGTCCCTAATCTACCCCTAATAGCCATGTGGTCACGTGTA  
 GTCAGTGAACCCATCTCATTCTCCTCATACTTTTCATCTCTAAATGAGGGTATAATTAAAGCTGTTCAATT  
 TTTTTTGAGATAGAGTTGCTCTGTCACCCAGGTTGGAGTGCATGGCACGATCTCAGCTACTGCAACCCCTGCT  
 TCCTCGGTCAAGTGAATTCTCCCTGCTCAGCCTCCAAAGTGAGCCCCGGATTACAGGTGCCGCCACCACATCTGGGC  
 TAGATTTTTGATTTCAACATGTTGGCCAGGCTGGCTCGAACCCCTACCTCAGGTGATCCCTCGCCTGGCCTCTCA  
 AAGTGCCTGGATTACAGGTGTGAGCCACACGCCAGCCAAATCAGTTTTCTTTAAACACAAGGCTAACACAATC  
 AAAATACTAGGGGAGAAAAAAATAAGGCACTGTTATGTGTAACAGGCTTGTGCAATCCACTGGGGCAGA  
 CCAAATAACAGTAAGAATCAAATCTTTCATATAATCCTTCTTGCAGAATACATAAAATCCCACAAATGGCTTAT  
 CTTCCTTTTATGATATGTTGGAGATTGAGCTAAGTGCACAGATATTGCTTGGGTGTATAGACCACAAAGGACTGTG  
 TCTTGATGATGGTTGCATAAAATTACCTAGTTTACTTGATGTTACATGTTAGATTAGAGTATGAAATTAG  
 TAGGGAGGATTATTAACAAAGAACAGGGCAAGAGGGTAGAATTAAACCTCTCTAATACCTGTCACAAGTAGGCTTT  
 CAGAAACTCTACAACCCAAACATAAACTGGATAGTTAGAAAGCACACTCCAAAGGAAGGCGGTATGTTGCAAGTTG  
 AATCAGAAGAATAGAGCTATAGCAATCTCATTCTAGTAACATTAAGAGCCTGGTTATATTAGCAGTCATTAAG  
 ATTTAAAATTACATCTGCCGTCTTCTTACTCACAGATTTCGAGAGGTAATGTAATGATCACACGAGGTGAGAATC  
 ACTGCCCTTATAATGCGATTAAATGCATGAACAAAGTTCCAACAAATAACAGTAATAAAAGAAACATGTTAGC  
 TTAATAAGCCAGGTGCTGTACGACGTGTTACATGCTTCATGAACCTGGTAAACTGGTACTAGTATCTCTATTG  
 GACATGTGAGGAAACCAATGGAGTTGATAAACAGTAGAGTTAAATTACTCTTCAATTATATTGCTCAATCTCA  
 CAGACATCTGCTACCAAAAGCTATCATATCTAGACTCGA

**FIG. 14(cont'd-3)**

19/21





FIG. 15

SUBSTITUTE SHEET (RULE 26)


20/21

TESTCODE OF: vslnuc ck: 6724, 1 to: 1588  
WINDOW: 200 bp MARCH 14, 1999 20:25



**FIG. 16A**

TESTCODE OF: humoctosk.gb\_pr2 ck: 9544, 1 to: 1374  
WINDOW: 200 bp MARCH 14, 1999 20:23



**FIG. 16B**

**SUBSTITUTE SHEET (RULE 26)**

21/21



**FIG. 17**

**SUBSTITUTE SHEET (RULE 26)**

## SEQUENCE LISTING

<110> Srikantan, Vasantha  
Zou, Zhiqiang  
Moul, Judd W.  
Srivastava, Shiv

<120> PROSTATE-SPECIFIC GENE, PCGEM1, AND METHODS OF USING  
PCGEM1 TO DETECT, TREAT, AND PREVENT PROSTATE CANCER

<130> 4995.0053-003-04

<140>

<141>

<150> 60/126,469

<151> 1999-03-26

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 1603

<212> DNA

<213> Homo sapiens

<400> 1

aaggcactct ggcacccagt ttggaaactg cagtttaaa agtcataaat tgaatgaaaa 60  
tgatagcaaa ggtggaggtt tttaaagagc tatttatagg tccctggaca gcatctttt 120  
tcaatttaggc agcaacccttt ttgcctatg ccgtaacctg tgtctgcaac ttccctctaata 180  
tggaaatag ttaagcagat tcatagagct gaatgataaa attgtactac gagatgcact 240  
gggactcaac gtgacccctt caagtggca ggcttgggc atttgacact tcatgatatc 300  
atccaaagtg gaactaaaaa cagtcctgg aagaggacta tgacatcatc aggttgggag 360  
tctccagggc cagcggaccc ttggaaaag gactagaaag tgtgaaatct attagtctt 420  
gatatgaaat tctctgtctc tgaaaagca tttcatatc acaagacaca ggcctactcc 480  
tagggcagca aaaagtggca acaggcaagc agagggaaaa gagatcatga ggcatttcag 540  
agtgcactgt ctttcataat atttctcaat gccgtatgtt tggtttatt ttggccaagc 600  
ataacaatct gctcaagaaa aaaaaatctg gagaaaacaa aggtgcctt gccaatgtt 660  
tgtttcttt tgacaagccc tgagattct gaggggatt cacataaatg ggatcaggtc 720  
attcatttac gttgtgtgca aatatgatt aaagatacaa ctttgcaga gagcatgctt 780  
tcctaagggtt aggcacgtgg aggactaagg gtaaagcatt cttcaagatc agttaatcaa 840  
gaaagggtgtt ctttgcattc tggaaatgccc ttgttgcaaa tattggttat attgattttaa 900  
tttacactta atggaaacaa cctttaactt acagatgaac aaacccacaa aagcaaaaaa 960  
tcaaaagccc tacatatgtt ttcataatctt ctgtgtact ggattaaagg attcctgttt 1020  
gctttgggc ataaatgata atggaaatatt tccaggtatt gttaaaatg agggcccatc 1080  
tacaaattct tagcaatact ttggataatt ctaaaattca gctggacatt gtctaattgt 1140  
tttttatata catcttgct agaatttcaa attttaagta tgtgaaatcta gttaatttagc 1200

tgtgctgatc aattcaaaaa cattactttc ctaaatttta gactatgaag gtcataaatt 1260  
 caacaaatat atctacacat acaattatag attgttttc attataatgt cttcatctta 1320  
 acagaattgt ctttgatt gtttttagaa aactgagagt tttaattcat aattacttga 1380  
 tcaaaaaatt gtggaaacaa tccagcatta attgtatgtg attgttttta tgtacataag 1440  
 gagtcctaag cttggcct tgaagtctt tgtacttagt cccatgttta aaattactac 1500  
 ttatatactt aagcattat gttttcaat tcaatttaca tgatgtaat tatggcaatt 1560  
 ataacaaata taaaagattt cgaaatagaa aaaaaaaaaa aaa 1603

<210> 2  
 <211> 1579  
 <212> DNA  
 <213> Homo sapiens

<400> 2  
 gcggccgcgt cgacgcaact tcctctaatt gggaaatagt taagcagatt catagagctg 60  
 aatgataaaa ttgtacttcg agatgcactg ggactcaacg tgaccttattc aagtgagatg 120  
 gagtccttgcctt ctgtctccaa ggctggagcc caatgggttg atcttggctc actgcaacct 180  
 ccaccccttcca ggttcaaaccg ttcttcctgc ctcagcctcc caagtaactg ggattacagc 240  
 aggcttggtg catttgacac ttcatgat cagccaaagt ggaactaaaa acagctcctg 300  
 gaagaggact atgacatcat caggttggga gtctccaggg acagcggacc ctttggaaaa 360  
 ggactagaaa gtgtgaaatc tattatgtctt cgtatgaaa ttctctgtct ccgtaaaaagc 420  
 atttcatttatacagacac aggccctactc cttagggcagc aaaaagtggc aacaggcaag 480  
 cagagggaaa agagatcatg aggcatttca gagtcactg tcttttcata tatttctcaa 540  
 tgccgtatgt ttggtttat tttggccaag cataacaatc tgctcaaaaa aaaaaaaaaatct 600  
 ggagaaaaaca aaggtgcctt tgccaatgtt atgtttcttt ttgacaagcc ctgagatttc 660  
 tgagggaaat tcacataaat gggatcaggt catttcatttca cgttgtgtgc aaatatgatt 720  
 taaagataca acctttgcag agagcatgtt ttccttaaggg taggcacgtg gaggactaag 780  
 ggtaaagcat tcttcagat cagttatca agaaagggtgc tctttgcatt ctgaaatgcc 840  
 cttgttgcac atattggtaa tattgattaa atttacactt aatggaaaca accttttaact 900  
 tacagatgaa caaaccaccaaaa aatcaaaaagc cctacctatg atttcatttatac 960  
 ttctgttgcac ctggatttttttggatttcctgc ttgcttttgg gcataaatga taatggaaata 1020  
 tttccaggtt ttgtttaaaa tgagggccca tctacaaaatt cttagcaata ctttggataa 1080  
 ttctaaaattt cagctggaca ttgtcttaattt gtttttata tacatcttgc ttagaatttc 1140  
 aaatttttaag tatgttattttt tagttatca gctgtgttgc tcaatttcaaa aacattactt 1200  
 tcctaaattt tagactatga aggtcataaa ttcaacaaaat atatctacac atacaatttat 1260  
 agattgtttt tcattataat gtcttcatct taacagaattt gtctttgtga ttgttttttag 1320  
 aaaactgaga gttttaaattt ataattactt gatcaaaaaaa ttgtggaaac aatccagcat 1380  
 taattgtatg tgattttttt tatgttacata aggagtctt aagtttgc cttgaagtct 1440  
 tttgtacttta gtcccatgtt taaaattactt actttatatac taaagcattt atgttttca 1500  
 attcaatttta catgtatgttta attatggcaaa ttataacaaa tattaaagat ttgcggaaatag 1560  
 aaaaaaaaaaaa aaaaatctt 1579

<210> 3  
 <211> 1819  
 <212> DNA  
 <213> Homo sapiens

<400> 3

1819

<210> 4

<211> 1025

<212> DNA

<213> *Homo sapiens*

<400> 4

tttttcaat taggcagcaa ccttttgcc ctatgccgt aacctgtgtct gcaacttcct 60  
ctaattggga aatagttaag cagattcata gagctgaatg ataaaattgt actacgagat 120  
gcactggac tcaacgtgac cttatcaagt gaggcaggctt ggtgcatttg acacttcatg 180  
atatcatcca aagtggaaact aaaaacagct cctggaagag gactatgaca tcacatcagg 240  
gggagtcctcc agggacagcg gaccctttgg aaaaggacta gaaagtgtga aatctattag 300  
tcttcgatata gaaattctct gtctctgtaa aagcatttca tatttacaag acacaggcct 360  
actccttaggg cagcaaaaaag tggcaacagg caagcagagg gaaaagagat catqaaqqcat 420

ttcagagtgc actgtcttt catatattc tcaatgccgt atgtttgggtt ttatTTTggc 480  
caagcataac aatctgctca agaaaaaaaaa atctggagaa aacaaaggcg cctttgcCAA 540  
tgTTatgttt cTTTTgaca agccctgaga tttctgaggg gaattcacat aaatgggatc 600  
aggTCATTCA tttacgttgt gtgcaaataat gatttaaaga tacaacctt gcagagagca 660  
tgCTTccta agggttaggca cgtggaggac taagggtaaa gcattctca agatcaggtt 720  
atcaagaaaag gtgctcttt cattctgaaa tgccctgtt gcaaataattg gttatattga 780  
ttaaatttac acttaatgga aacaacctt aacttacaga tgaacaaacc cacaaaagca 840  
aaaaatcaaa agccctacct atgatttcat atttctgtg taactggatt aaaggattcc 900  
tgcttgcttt tgggcataaa tgataatgga atatTTccag gtattgttta aaatgaggc 960  
ccatctacaa attcttagca atactttgga taattctaaa attcagctgg acattgtcta 1020  
attgt 1025

<210> 5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Probe/Primer

<400> 5

tgcctcagcc tcccaagtaa c

21

<210> 6

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Probe/Primer

<400> 6

ggccaaaata aaaccaaaca t

21

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Probe/Primer

<400> 7

tggcaacagg caagcagag

19

<210> 8  
<211> 11801  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (7470)  
<223> Y may represent any of the four nucleotide bases

ccttttggaaa aacacatggc gcattgttaat atgtttggct tccagggttct atctccaaagg 2220  
ataatggac aaaatcacac ataaaatttat ttccaggggca cacagtttcc cttttagggaa 2280  
actcacagag gtagagagta atacaataat cacatttggaa tattcagtaa gtgagggtct 2340  
catagatctt atgtgtatgt caccatgtat ataattttgt taatctactag atgtatgaga 2400  
caagaaattt gaggaaatctt aactagagat taaaatcagg gatTTaaatc aaagaaacat 2460  
ttaaatgcct cctttattat ttaaatacctt gcatggaga atcattggaa aaaaaataaa 2520  
aagcatacaa cttgggaaa ttataaacca agaagaattt gttattctgg ttgatTTTT 2580  
tttcaggctc cgcacaggca acttacctt atctcttgc gatTTtttatt tcttggtaaa 2640  
atatacagaa atagttaaagc agattcatag agctgaatat aaaatTTact acgagatgca 2700  
ctgggactca acgtgacctt atcaagtgc ttatcagtga ggtgagcatt cttattcag 2760  
ataatggAAC ttattatcat aatctttgc ttatcgtatt gttgagctt actacttatt 2820  
catatttgcA tatgcatatt gagataatat catttcattt atttcagtac tgaacactaa 2880  
tcttcataaga gtaattgtga aagtttcaga ttgcactatt ttaactata tatctgtatg 2940  
ttatcttcat atatgttga ataacttata agcaattgaa actttcaatt acagtatact 3000  
attgaagcaa atcaactaat atatacacat atccatttgc aatagtagat aatTTttgt 3060  
aatgtccagc acagttcttc atatgttagag gatgttcaaa ttggcttaagt tcctttctc 3120  
tcttaattat tagtatttt cctactgttc tttgtataat tattccttcc tctttagctc 3180  
caatccttac aatcttattct taacatagca actgggaaga aagtttttaa acataaaacca 3240  
gatgatgtca ctccacccca caaaacttcc actattctct gtcacacata gaaagaaaaga 3300  
aaaaaaatat tgaaaaccta caaagacttg ctatgtctg gtccaggctc tccctaaaat 3360  
ttcatgtaat ttccagccac taggccttcc tggctctct tcaatctcat tagccttttc 3420  
actactacaa gtttagactgg gtttggccg aggtatttct tttttcata ttttgcctt 3480  
gccttagattt ctcttccaaat agatattcac aatttgcata tcatttctat atacgtgtca 3540  
aaaggTTTcc ttgtccaaaa tagcttcagt gaccacctga tctagaatag tctcgatcaa 3600  
aagtttctt tccctttctt caccacttga tatttatac aaacattttat ttgtgttaatt 3660  
tatgtgtttt tttgtttctt gtactagcat tatgtatgacc atactatttgc atgccccccca 3720  
aaaaataactt tcgagaatga cagggcaaaag ctaaaaataat taaatttat aatTTtgaca 3780  
taggcactat tgacaaaaaaag caattgtatgt tatgtatgtg tttagtctat gaaatagtac 3840  
tatttaaaag taattctctg aaatacaatt ttctaaaact aaaagcagca tatgtacatg 3900  
aaacacccaaa aaacttcctt atatttataca ctggaaagatt taaaatagta taagtagtaa 3960  
cttatttaat atattttgtat ttatTTtaattt aattttatag tatccaactc taatataatg 4020  
ccagtggtat ttgttcaaaa tattttatgt ttgtctattt atttttaatt tgcctaaaaa 4080  
ttatctttaaa tgaaaatttt tggtaataa atttggaaaat actgaaaccc tcatttccag 4140  
tctctgtggaa tcctaaagtt ttttagttgag aaaataattt ttctcttagag aatgaagtag 4200  
cttgcataact tggagaaatt tctgttaaat aaatgtatatt atcaacttctt attttcttca 4260  
atacgaaata tataaataattt tcagtcata tattttgca ggtgctatgc ttttgcTTcc 4320  
aatcataattt tctgacaaat atttggaaag tcaaaaacttg tcttctattt tgTTatttaa 4380  
aatttatatac actacttttg taaaacctta tactatcaaa tcataggccaa tttcagtttgc 4440  
atTTcattctt ggtgcagaat ataagtttat ccaagtaaaa caggagtccat ttcaaaaagat 4500  
tcctccact gactgagata ttccaaagcc aactttgcaaa aatttgcaga taaaatatta 4560  
tacttcttgc taccttcattt ttatTTgttc aatttttctt tttgtttgtt gaaaattttt 4620  
atattttctt gtttcaagt tttgatttttta atttactact ttataatttt taaaggtaag 4680  
ttttgtgagg ctatattcat tatgtgtttt gaataaaagac atacaattaa ttttggaaac 4740  
tgcaataaaaa attataagac tattaaaaat gcagtaagtgc tactacactt aggctgtca 4800  
aaatgcagta ccagtagact acatTTtaggc tgcttaaagt tagttcttctt aagtaccata 4860  
tactttaaaaa ttttagctaa tgatggagaa caaagacaga aagactgtgt taccatattc 4920  
tagttggccca ttttgggggg ttttggagaga cgtcacatca gccttcat taaaattttt 4980  
tggTTTTacc attttgcattt tgagccaaat atacagcata atatacaaaaa taaaatataat 5040



tctcttggtt tacagagtag ctccataatac cccttgctgt ctgtctcaag tgcccaatgg 7980  
 gaagatagtc aaaacaatat tcacacctgt gattcatctc tctacatgca gtgtgtgtga 8040  
 atctttatatt actgcattt aaggatctgt cttagacat aaaaactaaa gcattgaagg 8100  
 aactccctgt tttgacttat caaagtccctt aagaaaatac tagaaaattt tagccattgt 8160  
 ttcaaaatttt agctttatatt tattacttga aatgtgatgaa aatgtggctg atagataata 8220  
 attcaactgat aacctacaga caattcccat cttaaaatgg accattggat tgaagaatta 8280  
 aataaaaattt agggtttcc ttacatgttt tgcataaaga gcgaaatgaga aacaactgtt 8340  
 catagatctt cattgaggat tcgcatgtga agtaagtact cctaacataa acaagtggac 8400  
 ttatcaacca agttccataa atcatgaaca aaaatattt tccccagaga gactatttt 8460  
 ccaccacatc tcttgtaata aacacagagc ccagttcagt taaaatagtt taagggtgga 8520  
 cggttcaggg cctgctgagt ggcactcagt aagaaaaccc agcagaacat ttacttctct 8580  
 ctttattcca gagcatcaat ggccaaggct ggaagatccc agaacactgaa acagacattt 8640  
 ggtctcttat ggcctgcca gttcacagt gggttccaaac gctttgggtc aaacccaaat 8700  
 agacctgtta gaaaaatgtc ggttggata cgctaacaat aagacagaat aaatgtgatt 8760  
 atttcacccctt attttatac gacttgatgtt attttattt aacattctt gggctggaa 8820  
 aatctgaatg ttaggacacc aaataatctcc agaaaacaag tttatattt ctaatcctgc 8880  
 ataataaaacc tggggccact gcaggcctca ttaataaaaa cctaatggta taacaataat 8940  
 gaggagggaaa tgccaatgcc gcacaaaatct gttgagacta aaatatttctt caccggcagca 9000  
 ggcttgggtgc atttgacact tcatgatatc agccaaatgt gaaactaaaaa cagctccctgg 9060  
 aagaggacta tgacatcatc aggttgggag tctccagggc cagggaccc tttggaaaaag 9120  
 gactagaaag tgcataatctt attagtcttc gatatggaaat tctctgtctc tgcataaagc 9180  
 atttcatatt tacaagacac aggcctactc ttagggcagc aaaaagtggc aacaggcaag 9240  
 cagagggaaa agagatcatg aggcatatca gactgcactg tctttcata tatttctcaa 9300  
 tgccgtatgt ttggttttt tttggccaag cataacaatc tgctcaagaa aaaaaaatct 9360  
 ggagaaaaca aagggtgcctt tgccaatgtt atgtttctt ttgacaagcc ctgagatttc 9420  
 tgaggggaat tcacataat gggatcaggt cattcattt cgttgcgtgc aaatatgatt 9480  
 taaagataca acctttgcag agagcatgct tccctaaggg taggcacgtg gaggactaag 9540  
 ggtaaagcat tcccaagaa tcagttatc aaagaaaatgt gcttttgc ttctgaaatg 9600  
 cccttgggtgc aaatatttgc tatatttgc aaatttacac ttaatggaaa caacctttaa 9660  
 cttacagatg aacaaacccca caaaagcaaa aaatcaaaag ccctacctat gatttcatat 9720  
 tttctgtgtt actggattaa aggattccctg ctgttttgc ggcataaaatg ataatggaaat 9780  
 atttccaggt attgtttaaa atgagggccc atctacaaat tcttagcaat actttggata 9840  
 attctaaaat tcagctggac attgtctat tttttttt atacatctt gctagaattt 9900  
 caaattttaa gtatgtaat ttgttaatt agctgtgtc atcaattcaa aaacattact 9960  
 ttcctaaattt ttagactatg aagggtcataa attcaacaaa tatatctaca catacaatta 10020  
 tagattgtt ttcattataa tgctttcata ttaacagaat tgctttgtt attgtttta 10080  
 gaaaactgag agttttaaat cataattacg ttgatcaaaa aattgtggga acaatccagc 10140  
 attaattgtt tgcattgtt tttatgtaca taaggagtct taagcttggt gccttgaagt 10200  
 cttttgtact tagccccatg tttaaaattt ctactttata tctaaagcat ttatgtttt 10260  
 caattcaatt tacatgtatgc taattatggc aattataaca aatattaaag atttcgaaat 10320  
 agaataatgtt aattgttcac catacataga aatgaaaatgt tcatttcgtt aagcaagatg 10380  
 ctgggtgaaa gactgtttt gattgaaaga tcacttagatt agtagaggc aagactttt 10440  
 gtccttaatc tacccttaat agccatgtgg tcacgttgc gtcactgttccatctt 10500  
 ctccctatc ttttttcatc tctaaaatgtt gggataattt taagctgtt cattttttt 10560  
 ttttttgcgat atagagttt gctttgttca cccaggttgg agtgcataatgg cacgatctca 10620  
 gctactgca accctctgtt tcctcggttca aagtgttctt ccctgcttca gcctcccaag 10680  
 tgagccccggg attacagggtt cccggccacca catctggcc tagattttt gtatatttgcac 10740  
 catgttggcc aggctggtct cgaaccccta cctcagggttca tccctcgctt cggccctctca 10800

aagtgcgtgg attacaggcg tgagccacca cgcccgcccc aatatcggtt tttctttttt 10860  
 aacacaaggc tAACACAATC aaaatactag cttaggggaga aaaaaaaaaat aaggcactgt 10920  
 ttatgtgtaa caggctcttg ttgcaatcca ctggggcaga ccaaataaac agtaagaatc 10980  
 aaatcccttt catataatcc ttctttgca gaatacataa aatccccaca aatggcttat 11040  
 ctccctttt atgatatgtt ggagaattgt agctaagtga cagatattt gcttgggtgt 11100  
 atagaccaca aaggactgtg tcttgatgtat ggtttgcata aaattatacc ttagtttta 11160  
 ctttgtatgt tacatgttag atttagagta tgaaaatttag tagggaggat tattaacaaa 11220  
 gaacaggcga agaggagtag aattaaacctt ttcttaataac ctgtgcacaa gtaggccttt 11280  
 cagaaactct acaaccccaa cataaaactgg atagtttagaa aagcacactt ccaaggaagg 11340  
 cggttatgtt ttgcagttt aatcagaaga atagagctat agcaatctt attctatagt 11400  
 aacattaaag agcctggttt atattatagc agtcattaag attaaaaat ttacatctt 11460  
 ccgttcttct tactcacaga ttttcgagag gtaatgtaat gatcacacga ggtgagaatc 11520  
 actgcctttt ataatgcgt taaatgcgt aacaaagttt ccaacaaata acagtaataa 11580  
 aaagaaaacat gtattagcac ttaataagcc aggtgctgtt cgacgtgtgt tacatgcttt 11640  
 caatccatga actgtaaaac tggtactagt atctctattt gacatgtgag gaaaccaaatt 11700  
 ggagttgata aacagtagag ttaaaaattt ctcttcataat attatattgc ctcaatctca 11760  
 cagacatctc tgctacccaa agctatcata tctagactcg a 11801

&lt;210&gt; 9

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 9

tggcaacagg caagcagag

19

&lt;210&gt; 10

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 10

ggccaaaata aaaccaaaca t

21

&lt;210&gt; 11

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 11

gcaaatatga tttaaagata caac

24

&lt;210&gt; 12

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 12

ggttgtatct tttaatcata tttgc

25

&lt;210&gt; 13

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 13

actgtctttt catatatttc tcaatgc

27

&lt;210&gt; 14

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 14

aagtagtaat tttaaacatg ggac

24

&lt;210&gt; 15

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 15

ttttcaatt aggtagcaac c

21

&lt;210&gt; 16

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 16

gaattgtctt tgtgattgtt tttag

25

&lt;210&gt; 17

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 17

caattcacaa agacaattca gttaag

26

&lt;210&gt; 18

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 18

acaatttagac aatgtccagc tga

23

&lt;210&gt; 19

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 19

ctttggctga tatcatgaag tgtc

24

&lt;210&gt; 20

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 20

aacctttgc cctatgccgt aac

23

&lt;210&gt; 21

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 21

gagactccca acctgatgat gt

22

&lt;210&gt; 22

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Probe/Primer

&lt;400&gt; 22

ggcacgttg agtcccagtg

20

## INTERNATIONAL SEARCH REPORT

Intern'l Application No  
PCT/US 00/07906

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/11 C12N9/00 C12Q1/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	"AC AC003046" EBI DATABASE, XP002143197 the whole document	5
X	SRIKANTAN V ET AL: "Structure and expression of a novel prostate specific gene: PC-GEM1." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03), page 37 XP000929230 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999 ISSN: 0197-016X abstract	1-7, 10, 11

Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the Invention

"X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

24 July 2000

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentdaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

2

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

Internr Application No  
PCT/US 00/07906

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 00498 A (HUMAN GENOME SCIENCES INC ; HE WEI WU (US); CARTER KENNETH C (US)) 7 January 1999 (1999-01-07) the whole document	1-17
A	BUSSEMAKERS M J G ET AL: "A NEW PROSTATE-SPECIFIC MARKER, STRONGLY OVEREXPRESSED IN PROSTATIC TUMORS" UROLOGICAL RESEARCH, DE, SPRINGER VERLAG, BERLIN, vol. 25, no. 1, 1 February 1997 (1997-02-01), page 76 XP002074305 ISSN: 0300-5623 abstract	1-17
A	WO 95 19434 A (CALYDON INC) 20 July 1995 (1995-07-20) the whole document	12-15
A	WANG ZHOU ET AL: "Genes regulated by androgen in the rat ventral prostate." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 12999-13004, XP002143199 Nov. 25, 1997 ISSN: 0027-8424 the whole document	16
P, X	"AC AC013401" EBI DATABASE, XP002143200 the whole document	1-5

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/US 00/07906

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9900498	A 07-01-1999	EP	0996725	A 03-05-2000
WO 9519434	A 20-07-1995	US	5830686	A 03-11-1998
		AU	692837	B 18-06-1998
		AU	1686995	A 01-08-1995
		CA	2181073	A 20-07-1995
		EP	0755443	A 29-01-1997
		JP	9509049	T 16-09-1997
		US	5648478	A 15-07-1997
		US	6057299	A 02-05-2000

Form PCT/ISA/210 (patent family annex) (July 1992)

